

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12P 17/02, C12N 3/00, 1/00, 15/01, 1/20, C12P 7/62, 7/26 // (C12P 17/02, C12R 1:07) (C12P 17/02, C12R 1:125)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/32651 (43) International Publication Date: 1 July 1999 (01.07.99)</p>
<p>(21) International Application Number: PCT/CA98/01150 (22) International Filing Date: 18 December 1998 (18.12.98) (30) Priority Data: 08/995,960 22 December 1997 (22.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/995,960 (CIP) Filed on 22 December 1997 (22.12.97) (71) Applicant (for all designated States except US): BCM DEVELOPMENT INC. [CA/CA]; Suite 218, 125 rue Dalhousie, Québec, Québec G1K 4C5 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): PAGE, Michel [CA/CA]; Suite 218, 125 rue Dalhousie, Québec, Québec G1K 4C5 (CA). LAJDRY, Nathalie [CA/CA]; 1060 de la Voie Ouest, St-Jean-Chrysostome, Québec G6Z 1K1 (CA). BOISSINOT, Maurice [CA/CA]; 109 Jean Bruchési, Saint-Augustin, Québec G3A 2N2 (CA). HELIE, Marie-Claude [CA/CA]; 453 Place St-Laurent,</p>	<p>Cap-Rouge, Québec G1Y 3G9 (CA). HARVEY, Mario [CA/CA]; 1067-F De la Prairie, St-Jean-Chrysostome, Québec G6Z 2G3 (CA). GAGNE, Martin [CA/CA]; 6400 Pise, Charlesbourg, Québec G1H 7A7 (CA). (74) Agents: COTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: BACTERIAL MASS PRODUCTION OF TAXANES AND PACLITAXEL (57) Abstract The present invention relates to a method of obtaining different biologically pure cultures of bacteria isolated from different species of <i>Taxus</i> such as <i>Taxus canadensis</i>, <i>T. brevifolia</i>, <i>T. baccata</i>, <i>T. cuspidata</i>, and <i>T. hunnewelliana</i>, wherein the bacteria produce <i>in vitro</i> taxanes and paclitaxel, and wherein the bacteria are of the genus <i>Sphingomonas</i>, <i>Bacillus</i>, <i>Pantoea</i> or <i>Curtobacterium</i>. Also, the present invention relates to a method of a bacterial mass production of at least one taxane or paclitaxel. There is also disclosed a novel bacterial taxane. The present invention also relates to the use of different biologically pure cultures of bacteria isolated from different species of <i>Taxus</i>, wherein the bacteria are able to biotransform pro-taxanes. There is also provided a process for improving taxanes and paclitaxel production of taxanes and paclitaxel producing bacteria which include culturing bacteria in the presence of a mutagenic agent for a period a time sufficient to allow mutagenesis. There is disclosed two new mutated bacterial which have an increased yield of pro-taxane biotransformation.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BACTERIAL MASS PRODUCTION OF TAXANES AND PACLITAXELBACKGROUND OF THE INVENTION(a) Field of the invention

5 The present invention relates to the production of paclitaxel and derivatives thereof (such as related taxanes) using a plurality of different bacteria isolated from different species of *Taxus*, and also to a novel taxane. There are disclosed methods for the isolation of these bacteria and the screening tests that
10 were used to provide evidence that paclitaxel and taxanes were produced by said bacteria. There are also disclosed methods for the biotransformation of pro-taxanes by said bacteria.

15 (b) Description of prior art

 Paclitaxel, also referred to as Taxol™, has been first identified in 1971 by Wani and collaborators (Wani MC et al., 1971 *J. Am. Chem. Soc.*, 93: 2325-2327) following a screening program of plant extracts of the
20 National Cancer Institute. This complex diterpene showed cytotoxic activity against several types of tumors and is presently used in the treatment of some cancers such as ovarian and breast cancers. Clinical studies suggest that Taxol™ could eventually be used in
25 the treatment of over 70% of human cancers.

 Paclitaxel differs from other cytotoxic drugs by its unique mechanism of action. It interferes with cell division by manipulating the molecular regulation of the cell cycle. Paclitaxel binds to tubulin, the
30 major structural component of microtubules that are present in all eukaryotic cells. Unlike other antimetabolic agents such as vinca alkaloids and colchicine,

which inhibit the polymerization of tubulin, paclitaxel promotes this assembly of tubulin and stabilizes the resulting microtubules. This event leads to the interruption of cell division, and ultimately to cell death.

5 The major obstacle in the use of paclitaxel as an anticancer treatment is its supply. It was originally isolated from the bark and leaves of yew trees such as *Taxus brevifolia*, *T. baccata*, *T. cuspidata* or, *T. canadensis*. The low yield of the isolation of
10 paclitaxel (0,016 g%) and the limited availability of the trees have forced the scientific and industrial community to find alternative ways of producing paclitaxel.

 The antitumor property of taxoid compounds has
15 also lead to the generation of new anticancer drugs derived from taxanes. Taxotere™ (sold by Rhône-Poulenc Rorer), which is produced from 10-deacetylbaccatin III by hemisynthesis, is currently used in the treatment of ovarian and breast cancers. Furthermore, Abbott Laboratories
20 is conducting clinical trials with a drug derived from 9-dihydro-13-acetyl baccatin III, a natural precursor specific to *Taxus canadensis*. The increasing demand for taxanes highlights the urgent need for renewable and economical processes that would
25 not endanger plant species.

 Presently, industrials are producing paclitaxel through hemisynthesis from baccatin III, a natural precursor of paclitaxel. However, this process still relies on a plant substance that must be extracted from
30 yew trees. The first complete chemical synthesis of paclitaxel has been achieved in 1994 by Nicolaou et al. (1994, *Nature*, 367:630-634). This is a multistep proc-

ess and the overall yield has made this approach non economically feasible.

Plant cell culture of *Taxus* species is another approach explored by many groups (Yukimune et al., 5 1996, *Nature Biotechnology*, 14:1129-1132; Srinivasan et al., 1995, *Biotechnology and Bioengineering*, 47:666-676). Somehow, this process is limited by the amount of paclitaxel that can be produced, the length of incubation time required to obtain significant yields, and 10 the application of plant cell culture to the large volumes required by the industry.

In United States Patent No. 5,322,779, in the names of Gary A. Strobel et al. disclosed a fungus isolated from the bark of a sample of *Taxus brevifolia* 15 which is able to synthesize paclitaxel at a level of 24-50 ng/l after a period of incubation of 3 weeks. Later, Strobel et al. (1996, *Microbiology*, 142:435-440) reported another fungus, *Pestalotiopsis microspora*, isolated from the inner bark of *Taxus wallachiana* that 20 can produced up to 55 µg/l of paclitaxel within 5 weeks. Somehow, the long periods of incubation and the large volumes required to extract significant amounts of paclitaxel reduce the profitability of the process.

In United States Patent number 5,561,055 (issued 25 on October 1, 1996 in the names of Michel Pagé et al., the Applicant), there is disclosed one bacterium, which was referred to as *Erwinia taxi*, for the production of paclitaxel. Since then, this bacteria has been characterized as *Sphingomonas taxi*. This bacterium was 30 isolated from *Taxus canadensis*. It would be highly desirable to be provided with other bacteria having

highly diverse metabolic capacities isolated from different species of *Taxus* for the production of paclitaxel and related taxanes at higher yields.

It would also be highly desirable to be provided with widely different bacteria for the mass production of various different bacterial taxanes.

As mentioned in International Patent Application published under number WO97/16200, biotransformation process may be used for the generation of new taxanes molecules that lead to new therapeutic drugs. It would also be highly desirable to be provided with new strains of microorganisms able to biotransform taxanes compounds for use as therapeutic agents or to be modified by hemisynthesis.

Genetic manipulations of bacteria can increase the activity or the production of certain proteins. It would also be highly desirable to be provided with mutant of our original isolates that could produce and biotransform taxanes at higher levels.

SUMMARY OF THE INVENTION

One aim of the present invention is to provide a plurality of bacteria for the mass production of taxanes and paclitaxel.

Another aim of the present invention is to provide a method for bacterial mass production of taxanes and paclitaxel which overcomes all the drawbacks of the prior art.

Another aim of the present invention is to provide a novel process for the production of taxanes and paclitaxel. The industrial application of this process would provide alternative renewable sources of taxoids

compounds for the pharmaceutical industry.

Another aim of the present invention is to provide a biotransformation process in which plant-derived taxanes are converted into substances that may be useful for the production of other therapeutic compounds.

In accordance with the present invention there is provided a method to obtain biologically pure cultures of bacteria isolated from *Taxus*, wherein said bacteria produce de novo taxanes and paclitaxel at a concentration of about 1 to 25 µg/L, wherein said bacteria are isolated from the inner surfaces of different species of *Taxus* including without limitations *Taxus canadensis*, *T. brevifolia*, *T. hunnewelliana*, *T. baccata*, and *T. cuspidata*.

In addition, said bacteria are capable of producing biotransformed taxanes wherein pro-taxanes are added to their culture medium.

Such biologically pure cultures of bacteria of the present invention include, without limitation, bacteria of the genus selected from the group consisting of *Sphingomonas*, *Bacillus*, *Pantoea*, and *Curtobacterium*.

In accordance with the present invention, the bacteria include, without limitation, *Bacillus cereus* ssp. *taxi*, *Bacillus megaterium* ssp. *taxi*, *Pantoea* sp. BCM 1, *Pantoea* sp. BCM 2, *Pantoea* sp. BCM 3, *Bacillus cereus* ssp. BCM 4, *Bacillus subtilis* ssp. *taxi*, *Bacillus megaterium* ssp. BCM 9 or *Curtobacterium* sp. BCM 5.

In accordance with the present invention there is also provided a method of bacterial mass production of taxanes and paclitaxel thereof which comprises the steps of:

- 5 a) culturing the bacteria of the present invention in a growth-supporting nutrient medium capable of promoting growth and reproduction of said bacteria, and wherein said culturing is effected for a time sufficient to allow production of taxanes and paclitaxel; and
- b) isolating said produced taxanes and paclitaxel from said bacteria or culturing medium of step a).

10 In accordance with the present invention there is also provided a process for improving taxanes and paclitaxel production of taxanes and paclitaxel producing bacteria comprising the steps of:

- 15 a) culturing bacteria in the presence of a mutagenic agent for a period of time sufficient to allow mutagenesis;
- b) selecting said mutants by a change of the phenotype which results in an increased production of taxanes and paclitaxel.

20 The mutagenic agent may be a chemical agent, such as daunorubicin and nitrosoguanidine.

The mutagenic agent may be a physical agent, such as gamma radiation or ultraviolet.

25 The mutagenic agent may be a biological agent, such as a transposon.

In accordance with the present invention, the mutated bacteria include, without limitation, *Sphingomonas taxi* D200 or *Sphingomonas taxi* D201.

30 In accordance with the present invention there is also provided a method of bacterial biotransformation of taxanes and paclitaxel thereof which comprises the steps of:

a) incubating the bacteria of the present invention in a growth-supporting nutrient medium capable of promoting growth and reproduction of said bacteria, and wherein said incubation is effected in the presence of pro-taxanes for a time sufficient to allow production of taxanes and paclitaxel; and

b) isolating said produced taxanes and paclitaxel thereof from said culturing medium of step a).

10 In accordance with the present invention, there is also provided a process for improving biotransformation of pro-taxanes into taxanes and paclitaxel by taxanes and paclitaxel-producing bacteria comprising the steps of:

15 a) culturing bacteria in the presence of a mutagenic agent for a time sufficient to allow mutagenesis; and

b) selecting said mutants by a change of the phenotype which results in an increased biotransformation of pro-taxanes into taxanes and paclitaxel.

20 In accordance with the present invention there is also provided a method of bacterial biotransformation of pro-taxanes into taxanes and paclitaxel thereof which comprises the steps of:

25 a) incubating the mutated bacteria of the present invention in a nutrient medium, and wherein said incubation is effected in the presence of pro-taxanes for a time sufficient to allow production of taxanes and paclitaxel; and

30 b) isolating said produced taxanes and paclitaxel thereof from said culturing medium of step a).


In accordance with the present invention there is also provided a novel bacterial taxane having a characteristic ultraviolet spectrum in HPLC as shown in Fig. 9B, Electrospray Ionization (EI) spectrum as shown in Fig. 10A, and characteristic fragments as shown in Fig. 10B.

This novel bacteria-derived taxane of the present invention is produced by at least two species of *Bacillus* (*B. cereus* ssp. *taxi* and *B. megaterium* ssp. *taxi*).

For the purpose of the present invention the following terms are defined below.

The term "taxanes and paclitaxel" is intended to mean any paclitaxel derivatives or precursor which have retained or not the taxol-associated cytotoxic biological activity or are thought to be precursors in the synthesis of paclitaxel. Such taxanes and paclitaxel may be selected from the group consisting of all the diterpenes isolated from any *Taxus* species. The production of all taxanes by bacteria, whether pharmacologically active or inactive, is contemplated within the scope of the present invention. Taxanes that are produced by the bacteria of the present invention may be as such found in *Taxus* plant species or may differ from the ones found in *Taxus* plant species.

Exemplary taxanes which may be produced by the bacteria of the present invention include but are not limited to those of the following Formula I:



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} ,
5 R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1 below.

However, since bacteria have highly diverse metabolic capacities the taxanes and paclitaxel must only correspond to Formula I, whatever is the nature of R_1 to R_{17} substituents.

10 The term "pro-taxanes" used in accordance with the present invention is intended to mean any precursors of any taxanes in the biosynthesis pathway of paclitaxel in plant, fungi and bacteria, including, without limitation, 10-deacetylbaccatin III, baccatin
15 III, cephalomannine, taxinines, taxuspines, taxusin, 7-xylosyl taxol, 7-epi-10-deacetyl taxol, 10-deacetyl taxol, paclitaxel, 7-epitaxol, taxadiene, geranyl-geranyl-pyrophosphate (GGPP) and farnesyl-pyrophosphate.

20 Exemplary pro-taxanes which may be biotransformed by the bacteria of the present invention include but are not limited to those of the preceding formula I where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1 below.

25 Exemplary biotransformed taxanes of the present invention include, but are not limited to, those of the


following Formula I where $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}$ are defined in Table 1.

Table 1


Compound	R ₁ ⁽¹⁾	R ₂	R ₃	R ₄	R ₅	R ₆ ⁽²⁾	R ₇ ⁽³⁾	R ₈ R ₁₇	R ₉ R ₁₀ ⁽⁴⁾	R ₁₁	R ₁₂ ⁽⁵⁾	R ₁₃	R ₁₄	R ₁₅ ⁽⁶⁾	R ₁₆
1) paclitaxel	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
2) 10-deacetyl- cephalomannine	ceph	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
3) 7-epitaxol	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
4) 10-deacetyl-7- epitaxol	tax	CH ₃	H	β-OH	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
5) 7-epi- cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
6) baccatin III	α-OH	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
7) 10-deacetyl baccatin III	α-OH	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
8) cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
9) 10-deacetyl taxol	tax	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
10) 7-xylosyl taxol	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-xylosyl	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
11) 7-xylosyl- cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-xylosyl	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
12) taxagifine	=O	α-CH ₃	β-OH	β-acetyloxy	α-acetyloxy	β-CH ₃	β-acetyloxy	H	α-dimamoyloxy	methylene (=CH ₂)	α-acetyloxy	β-H	H	cyclo	α-CH ₃
13) 8-benzoyloxy- taxagifine	=O	α-CH ₃	β-OH	β-acetyloxy	α-acetyloxy	β-benzoyloxy oxymethyl	β-acetyloxy	H	α-dimamoyloxy	methylene (=CH ₂)	α-acetyloxy	β-H	H	cyclo	α-CH ₃
14) 9-acetyloxy- taxusin	α-acetyloxy	CH ₃	H	β-acetyloxy	α-acetyloxy	β-CH ₃	H	H	α-acetyloxy	methylene (=CH ₂)	H	H	H	CH ₃	CH ₃
15) 9-hydroxy-taxusin	α-acetyloxy	CH ₃	H	β-acetyloxy	α-OH	β-CH ₃	H	H	α-acetyloxy	methylene (=CH ₂)	H	H	H	CH ₃	CH ₃
16) taxane Ia	tax	CH ₃	H	=O	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
17) taxane Ib	taxsub	CH ₃	H	=O	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
18) taxane Ic	taxsub	CH ₃	H	=O	=O	β-CH ₃	α-acetyloxy	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
19) taxane Id	α-acetyloxy	CH ₃	H	β-acetyloxy	α-acetyloxy	β-CH ₃	β-acetyloxy	H	α-OH	epoxide	α-acetyloxy	β-OH	H	CH ₃	CH ₃
20) 7-epibaccatin III	α-OH	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃

Footnotes

(1) "ceph" denotes




"tax" denotes




5


"taxsub" denotes



(2) "xylosyl" denotes



10 (3) "α" denotes the stereoposition of a stereomoiety below the plane of the taxane ring structure shown above



15 "β" denotes the stereoposition of a moiety above the plane of the taxane ring structure shown above



(4) "oxetane" denotes the moiety



20 which is




5) "cyclo" denotes the cyclic group formed by bonding the group



to the taxane

A ring as follows:



6) "epoxide" denotes the moiety



5

which is



The term "taxol-associated cytotoxic biological activity" is intended to mean a cytotoxic activity which is sufficient to promote the assembly of tubulin and stabilizes the resulting microtubules of cancer cells causing the division of the cells in two equal daughter cells to be interrupted; and sufficient to cause a disruption in the dynamic equilibrium which exists between microtubules and their depolymerized tubulin dimers, thus preventing completion of the mitotic step which causes a lethal metaphase arrest of cancer cells.

The expression "cancer cells" is intended to mean any cancer cells which include without limitation, ovarian, breast, lung, head and neck cancer cells.

The term "growth supporting nutrient medium" is intended to mean any culture media which include, without limitation, carbon sources, nitrogen sources, amino acids, vitamins and minerals.

The term "intercalating agent" is intended to mean any molecule binding to the double stranded DNA structure which include, without limitation, daunorubicine, ethidium bromide, acridine orange, acriflavine and epirubicine.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A shows the elution profile, according to HPLC method no. 1, of an organic supernatant extract of a bacteria in accordance with one embodiment of the present invention, referred to as *Sphingomonas taxi*;

Fig. 1B illustrates the UV spectra of paclitaxel obtained from a standard and of an organic extract of supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Sphingomonas taxi*;

Fig. 2A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus cereus* ssp. *taxi* using HPLC method no. 2;

Fig. 2B illustrates the ultraviolet spectrum of paclitaxel produced by *Bacillus cereus* ssp. *taxi* compared to a paclitaxel standard;

Fig. 2C illustrates the ultraviolet spectrum of 7-xylosyl-10-deacetyltaxol produced by *Bacillus cereus* ssp. *taxi* compared to an authentic standard co-eluting with taxinine M;

Fig. 3A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Pantoea* sp. BCM 1 using HPLC

method no. 2;

Fig. 3B illustrates the ultraviolet spectrum of 7-epi-10-deacetyltaxol produced by *Pantoea* sp. BCM 1 compared to an authentic standard;

5 Fig. 4A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus megaterium* ssp. *taxi* using HPLC method no. 2;

10 Fig. 4B illustrates the ultraviolet spectrum of the bacterial paclitaxel produced by *Bacillus megaterium* ssp. *taxi* compared to an authentic standard;

Fig. 5A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus cereus* ssp. BCM 4 using HPLC method no. 2;

Fig 5B shows a substance having the characteristic ultraviolet spectrum of a taxane compared to a standard of 7-xylosyl-10-deacetyltaxol co-eluting with taxinine M;

20 Fig. 6 illustrates the cytotoxicity of organic extracts of microorganisms isolated from different species of *Taxus* on CRL-1572 cell line as well as the cytotoxicity of taxanes and paclitaxel negative bacteria (STJ.BRP.K1 and *E. coli* TG1);

Fig. 7A illustrates the mass spectrometry of the substances eluted between 45 and 48 minutes using HPLC method no. 1 from an extract of *Sphingomonas taxi*;

30 Fig. 7B illustrates the mass spectrometry of a paclitaxel standard;

Fig. 8A illustrates the almost complete 16S rRNA

gene sequence of *Sphingomonas taxi* (SEQ ID NO:1);

Fig. 8B illustrates the almost complete 16S rRNA gene sequence of *Bacillus cereus* ssp. *taxi* (SEQ ID NO:2);

5 Fig. 8C illustrates the partial 16S rRNA gene sequence of *Bacillus megaterium* ssp. *taxi* (SEQ ID NO:3);

Fig. 8D illustrates the partial 16S rRNA gene sequence of *Pantoea* sp. BCM 1 (SEQ ID NO:4);

10 Fig. 8E illustrates the partial 16S rRNA gene sequence of *Bacillus cereus* ssp. BCM 4 (SEQ ID NO:5);

Fig. 8F illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus subtilis* ssp. *taxi* (SEQ ID NO:6);

15 Fig. 8G illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Pantoea* sp. BCM 2 (SEQ ID NO:7);

20 Fig. 8H illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Pantoea* sp. BCM 3 (SEQ ID NO:8);

Fig. 8I illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus megaterium* ssp. BCM 9 (SEQ ID NO:9);

25 Fig. 8J illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Curtobacterium* sp. BCM 5 (SEQ ID NO:10);

Fig. 8K illustrates the partial 16S rRNA gene

sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Sphingomonas* sp. BCM 7 (SEQ ID NO:11);

Fig. 9A illustrates a typical chromatogram of an organic extract from the supernatant of *Bacillus cereus* ssp. *taxi* producing a specific bacterial taxane using HPLC method no. 2;

Fig. 9B illustrates the ultraviolet spectrum of the characteristic taxane produced by *Bacillus cereus* ssp. *taxi*;

Fig. 10A illustrates the GC/MS (EI) spectrum of the purified specific bacterial taxane produced by *Bacillus cereus* ssp. *taxi* in accordance with the present invention;

Fig. 10B illustrates the mass-to-charge ratios of ions present in the EI mass spectra of the bacterial taxane produced by *Bacillus cereus* ssp. *taxi*;

Fig. 11A shows the evolution in time of two taxanes in the sterile culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* incubated at 150 rpm at 30°C;

Fig. 11B shows the evolution of two taxanes transformed by *Sphingomonas taxi* when cultured in the culture medium S-7 supplemented with 1% of an aqueous extract of *Taxus canadensis*, shaken at 150 rpm at 30°C;

Fig. 12 shows the HPLC chromatograms of *S. taxi* cultured in the S-7 culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* where sample name 8A represents the organic extract of the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, sample name S 24 hres represents the organic extract of *Sphingomonas taxi* incu-

bated 24 hours in the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, sample name S 48 hres represents the organic extract of *Sphingomonas taxi* incubated 48 hours in the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, and sample name S 72 hres represents the organic extract of *Sphingomonas taxi* incubated 72 hours in the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*;

Fig. 13 compares HPLC chromatograms of the supernatant extracts of *S. taxi* (sample name: S 48 hres), *S. taxi* D200 (sample name: SC 48 hres) and *S. Taxi* D201 (sample name: SCP 48 hres) cultured 48 hours in the medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, and the organic extract of the medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* (sample name 8A); and

Figs. 14A-14C show the characteristic ultraviolet spectrum of the new biotransformed pro-taxanes.

DETAILED DESCRIPTION OF THE INVENTION

Plants are hosts of a variety of microorganisms. The relation between the plant and the microorganism can be saprophytic, parasitic, endophytic or symbiotic. Whatever the relation, there may be genetic exchange between the species. *Taxus*, such as *Taxus canadensis*, which grows in some regions of the province of Quebec, shows significant amounts of paclitaxel in its needles and stems. Samples of *Taxus canadensis* from seven (7) regions of the province of Quebec were chosen as well as samples of different species of *Taxus* such as *Taxus*

brevifolia, *T. cuspidata*, *T. baccata*, *T. hunnewelliana*. Several different bacteria of different genus, such as *Sphingomonas*, *Bacillus*, *Pantoea*, and *Curtobacterium* were isolated from inner parts of samples from
5 different species of *Taxus*, and all demonstrated taxanes and/or paclitaxel-producing properties.

Bacteria described above, produced taxanes and paclitaxel in fermentation procedures. Bacteria are cultured in a appropriate growth supporting nutrient
10 medium containing ingredients known to those skilled in the art for the cultivation of microorganisms. Specific examples of appropriate such media are given below. Temperature of cultivation ranges from 10°C to 35°C, and aerobic cultivation is generally preferred.

15 Taxanes and paclitaxel are generally excreted in the supernatant, up to 10% of those substances remain in the cell. Taxanes and paclitaxel thereof may be extracted by performing an organic extraction with an appropriate solvents such as methylene chloride or
20 ethyl acetate.

In accordance with the present invention, various bacteria producing taxanes and paclitaxel were isolated from different species of *Taxus*.

One bacterium isolated from *Taxus canadensis*
25 allows for the production of taxanes and paclitaxel at a yield of 1 µg/L, referred to as *Sphingomonas taxi*, has been already deposited at the American Type Culture Collection but was identified as *Erwinia taxi* (ATCC, 12301 Parklawn Drive, Rockville, MD 20852 USA) on April
30 25, 1995 under deposit number ATCC 55669. The deposit is also available as required by Foreign Patent laws in

countries wherein counterpart applications are filed.

The other strains of the present invention have been deposited at the American Type Culture Collection (ATCC, 12301 Parklawn Drive, Rockville, MD 20852 USA) on December 18, 1997 under deposit accession numbers as set forth below. The deposit are also available as required by Foreign Patent laws in countries wherein counterpart applications are filed.

Strain	ATCC No.
<i>Bacillus cereus</i> ssp. <i>taxi</i>	202061
<i>Bacillus megaterium</i> ssp. <i>taxi</i>	202062
<i>Curtobacterium</i> sp. BCM5	202063
<i>Pantoea</i> sp. BCM2	202064
<i>Bacillus megaterium</i> BCM9	202065
<i>Bacillus cereus</i> BCM4	202066
<i>Sphingomonas</i> <i>taxi</i> D201	202067
<i>Sphingomonas</i> <i>taxi</i> D200	202068
<i>Sphingomonas</i> sp. BCM7	202069
<i>Pantoea</i> sp. BCM3	202070
<i>Pantoea</i> sp. BCM1	202071
<i>Bacillus subtilis</i> ssp. <i>taxi</i>	202072

10

In accordance with one embodiment of the present invention, the bacteria isolated from different species of *Taxus* allow for the production of taxanes and paclitaxel thereof at a yield of 1 to 25 µg/L.

15

In accordance with the present invention, the bacteria isolated from different species of *Taxus* may be employed for the biotransformation of pro-taxanes.

Isolation of the different microorganisms producing taxanes and paclitaxel

Each plant was divided into 5 parts; needles, twigs, stems, bark and roots. Each inner part of the
5 plant was verified for the presence of taxanes and paclitaxel producing microorganisms.

The surface of every part of the plant was sterilized with 95% ethanol and then, cut into small pieces with a sterile blade. Pieces were homogenized in sterile
10 water with a POLYTRON™ that had also been sterilized with ethanol 95%. The resulting mix was used to inoculate two different culture media; R2A agar (Difco) and Sabouraud agar (Difco).

Each plate was incubated at 22°C and examined on
15 a day-to-day basis. The morphology of each colony was meticulously noted and the bacteria were transferred on different media until a pure culture was obtained. A Gram coloration of every bacteria was done before the culture was frozen at -80°C.

Over 50 bacteria were isolated from different
20 samples of *Taxus canadensis* of the province of Quebec. In addition, over 30 different bacteria were isolated from different species of *Taxus* which include, without limitations, *Taxus brevifolia*, *T. baccata*, *T. cuspidata*, *T. hunnewelliana*. Some of them, showing taxanes
25 and paclitaxel production capacities, will be fully described below.

Screening of microorganisms

In order to verify the production of taxanes and
30 paclitaxel by microorganisms, each organism was cultured in at least 500 ml of a growth supporting nutrient medium. Any liquid medium allowing taxanes and

paclitaxel thereof production may be employed. Exemplary liquid media are S-7 media (Table 2), and defined media for *Bacillus* (Table 3). Every culture was performed in culture flasks and incubated at a temperature ranging from 20°C to 35°C with constant shaking until a sufficient growth was achieved, generally 18 to 72 hres.

Table 2

Composition of S-7 medium

Compounds	g/L
glucose	1
fructose	3
sucrose	6
sodium acetate	1
soytone	1
thiamine	0,001
biotine	0,001
pyridoxal-HCl	0,001
Ca pantothenate	0,001
MgSO ₄	0,0036
CaNO ₃	0,0065
Cu(NO ₃) ₂	0,001
ZnSO ₄	0,0025
MnCl ₂	0,005
FeCl ₃	0,002
phenylalanine	0,005
sodium benzoate	0,1
KH ₂ PO ₄ 1M (pH 6,8)	1 ml

Table 3Composition of the defined medium for *Bacillus*

Compounds	g/L
L-glutamic acid	10
glucose	5
citric acid	1
K ₂ HPO ₄	0,5
KH ₂ PO ₄	0,5
MgSO ₄ -7H ₂ O	0,2
MnSO ₄ -4H ₂ O	0,01
FeSO ₄ -7H ₂ O	0,01

The culture was then centrifuged and the pellet
5 separated from the supernatant by decantation. To ver-
ify if taxanes and paclitaxel were secreted in the
medium or if it was confined within the cells, both
were tested for the presence of the drug. Since tax-
anes and paclitaxel are hydrophobic, and in order to
10 concentrate each sample, an extraction with an organic
solvent was performed. For the pellet, the cells were
dried and about 200 mg were powdered and ultrasonicated
twice for 40 minutes in 3 ml methanol. The extracts
were dried at 25°C. The residue was dissolved by add-
15 ing 2 ml of methylene chloride and 2ml of distilled
water. After appropriate shaking, the mixture was cen-
trifuged at 4 000 rpm for 5 min. The methylene chlo-
ride fraction was collected and dried under reduced
pressure. Finally, the residue is dissolved in 0,5 ml
20 of HPLC grade methanol.

The supernatant is extracted with one volume of
methylene chloride. After appropriate shaking, the

organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in 50 ml of methylene chloride and 50 ml of distilled water. After appropriate shaking, each fraction was collected and dried under reduced pressure. Each residue is dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C.

a) HPLC screening

10 HPLC method no. 1

Some extracts were analyzed by High Performance Liquid Chromatography (HPLC) on a system consisting of a WATERS™ 625 LC pump, a WATERS™ 996 photodiode array spectrophotometer, and a WATERS™ 717plus autosampler. Chromatography was performed with a phenyl column from Waters (5µm particle size, 6 mm X 15 mm) with a guard module. The injection volume varies from 50 to 150 µl and the flow rate maintained at 1 ml/min. The following elution program was used;

20 0 to 20 min.: methanol:water:acetonitrile
(20:65:15) ramped to methanol:water:acetonitrile
(20:45:35)

20 to 50 min.: methanol:water:acetonitrile (20:45:35)
ramped to methanol:water:acetonitrile
25 (20:25:55)

50 to 60 min.: methanol:water:acetonitrile (20:25:55)
ramped to methanol 100%

Table 4 identifies the retention times of known authentic standards on HPLC methods no. 1 and no. 2. Using HPLC no. 1, paclitaxel has a retention time of 46 minutes. In Fig. 1, we show the ultraviolet spectrum

of paclitaxel produced by *Sphingomonas taxi*. The spectrum is very characteristic with a second maximum of absorption at 230nm. This figure illustrates that *Sphingomonas taxi* produces a compound having the same retention time and the same UV spectrum as paclitaxel.

HPLC method no. 2

Some extracts were analyzed on the same HPLC system with a curosil-PFP column (250 mm X 3.2 mm) from Phenomenex with a guard module. Injections varied from 50 ul to 150 ul and the flow rate maintained at 0.8 ml/min. The following gradient program was used;

0 to 50 min.: acetonitrile:water (25:75) ramped to acetonitrile:water (65:35)

50 to 62.5 min.: acetonitrile:water (65:35) ramped to methanol 100%

62.5 to 65 min.: methanol 100% to acetonitrile:water (25:75)

65 to 75 min.: acetonitrile:water (25:75)

As shown in Table 4, using HPLC method no. 2, paclitaxel is eluted at 36.987 minutes.

Table 4

Retention time of taxanes standards using HPLC methods
no. 1 and no. 2

Taxanes	Retention time using	
	HPLC method no. 1	HPLC method no. 2
10-deacetyl baccatin III	n/a	12.037 min.
baccatin III	n/a	20.670 min.
7-xylosyl-10-deacetyltaxol B	n/a	24.870 min.
7-xylosyl-10-deacetyltaxol and taxinine M	n/a	27.120 min.
7-xylosyl-10-deacetyltaxol C	n/a	28.770 min.
10-deacetyltaxol and 7-xylosyltaxol	n/a	30.770 min.
cephalomannine	n/a	34.753 min.
7-epi-10-deacetyltaxol	n/a	35.703 min.
paclitaxel	46 minutes	36.987 min.
taxol C	n/a	38.853 min.
7-epitaxol	n/a	42.287 min.

5 Fig. 2A shows a typical chromatogram of an organic extract of *Bacillus cereus* ssp. *taxi*, and in Figs. 2B and 2C there is compared the UV spectra of the substances produced by *Bacillus* with authentic commercial plant standards. This figure clearly illustrates
10 the ability of *Bacillus cereus* ssp. *taxi* to produce paclitaxel and 7-xylosyl-10-deacetyltaxol.

Fig. 3A shows the typical HPLC chromatogram of the supernatant of *Pantoea* sp. BCM 1 and, in Fig. 3B there is compared the bacterial 7-epi-10-deacetyltaxol
15 against an authentic commercial plant standard, establishing the production of 7-epi-10-deacetyltaxol by *Pantoea* sp. BCM 1.

Fig. 4A shows a typical chromatogram of *Bacillus megaterium* ssp. *taxi* and, in Fig. 4B there is compared
20 the ultraviolet spectrum of the bacterial paclitaxel

with an authentic standard proving the capacity of this bacterium to produce paclitaxel.

Fig. 5A shows a typical chromatogram of *Bacillus cereus* ssp. BCM 4 and, Fig 5B shows a substance having the characteristic ultraviolet spectrum of a taxane compared to a standard of 7-xylosyl-10-deacetyltaxol co-eluting with taxinine M, proving the capacity of *Bacillus cereus* ssp. BCM 4 to produce taxanes.

b) Cytotoxicity on cancer cells

10 An ovarian cancer cell line obtained from American Type Culture Collection (12301 Parklawn Drive, Rockville, MD 20852 USA) under ATCC accession number CRL-1572) was chosen for the investigation. Briefly, 2 000 cells/well of a 96-well microplate were inoculated.

15 After 2 days, different dilutions of the drug were added in a volume of 100 μ l. Three days later, the viability of cells was measured with ALAMAR™ blue (B. Pagé et al. 1993, *Intl. J. of Oncology*, 3:473-476). The ATCC CRL-1572 cell line is particularly sensitive

20 to paclitaxel (ID_{50} of 1 ng/ml). Microbial extracts have also been tested for their cytotoxicity on those cells. Fig. 6 shows the cytotoxicity of different bacterial supernatant extracts. This figure clearly demonstrates that culture supernatant extracts from *Sphingomonas taxi* and *Bacillus cereus* ssp. taxi are at least

25 5-fold more cytotoxic than extracts from non-paclitaxel producing bacteria such as STJ.BRP.K1 and *E. coli* TG1.

c) Mass spectrometry

30 Mass spectrometry of the substances eluted between 45 and 48 minutes with HPLC method no.1 from an

extract of *Sphingomonas taxi* was performed. Fig. 7A shows the results obtained. In every sample, a substance with a molecular weight (M.W.) of 853,5 daltons appears. The theoretical M.W. of paclitaxel is 854 daltons. Even if these extracts were partially purified, essentially the major compound obtained is paclitaxel.

d) Characterization of a bacterial taxane by EI/MS

Fig. 9A, shows a typical chromatogram of *Bacillus cereus* ssp. *taxi* producing a characteristic taxane having a retention time of 15 minutes using HPLC method no. 2. In Fig. 9B, the characteristic ultraviolet spectrum of this substance is illustrated. It was purified on HPLC using HPLC method no. 2 and, analyzed in Electro Ionization Mass Spectrometry (EI/MS) as described by Thomas D. McClure et al. (*J. Am. Soc. Mass Spectrom.*, 1992, 3, pp. 672-679).

Fig. 10A shows the EI spectrum of this taxane and Fig. 10B shows the characteristic fragments of this taxane. Since this taxane has never been observed in plant extracts of different species of *Taxus*, and this compound is produced by at least two species of *Bacillus* (*cereus* ssp. *taxi* and *megaterium* ssp. *taxi*), we consider this novel taxane unique to microorganisms isolated from *Taxus*.

Characterization of taxane and paclitaxel producing microorganisms

a) Biochemical and physiological characteristics

Table 5 shows the species of *Taxus* from which each bacterium was isolated, the Gram coloration, the

morphology of colonies on different culture media and, some biochemical characteristics. This Table clearly illustrates the diversity of our taxanes and paclitaxel producing bacteria i.e. we have isolated and identified

5 Gram-negative and Gram-positive rods including Actinomycetes from different species of *Taxus* which all possess taxanes and/or paclitaxel producing capacities.

Table 5

Cellular, morphological and biochemical characteristics
of some taxanes and paclitaxel producing bacteria

Name	Isolated from	Gram	Cellular morphology	Description of colonies on blood agar	Description of colonies on TA-1	Catalase	Urease
<i>Sphingomonas taxi</i>	<i>Taxus canadensis</i>	-	Rod	No growth	3 days to grow Orange-Opaque Glossy-Convex Circular contour	+	-
<i>Bacillus cereus</i> ssp. <i>taxi</i>	<i>Taxus canadensis</i>	+	Rod	Double hemolysis Gray-green- Opaque Dry-Dull-Flat Irregular edge	Cream- Opaque Dry-Dull-Flat Irregular edge	+	-
<i>Bacillus megaterium</i> ssp. <i>taxi</i>	<i>Taxus hunnewelliana</i>	+	Rod	Gray- Opaque Dry-Dull Convex Irregular edge	Cream- Opaque Glossy Slightly convex Irregular edge	+	-
<i>Pantoea</i> sp. BCM 1	<i>Taxus hunnewelliana</i>	-	Rod	Semi-translucent Glossy-Flat Regular edge	Cream with yellow pigment in middle Opaque-Glossy- Flat Regular edge	+	-
<i>Pantoea</i> sp. BCM 2	<i>Taxus cuspidata</i>	-	Rod	Yellow Opaque Glossy-Flat Regular edge	Yellow Semi-translucent Glossy-Flat Regular edge	+	-
<i>Pantoea</i> sp. BCM 3	<i>Taxus cuspidata</i>	-	Rod	Semi-translucent Glossy-Flat Regular edge	Yellow Semi-translucent Glossy-Flat Regular edge	+	-
<i>Bacillus cereus</i> ssp. BCM 4	<i>Taxus brevifolia</i>	+	Rod	Double hemolysis Gray-green- Opaque Dry-Dull-Flat Irregular edge	Cream- Opaque Dry-Dull-Flat Irregular edge	+	-
<i>Bacillus subtilis</i> ssp. <i>taxi</i>	<i>Taxus baccata</i>	+	Rod	Semi-translucent Dry, Dull Convex Regular edge	Cream- Translucent Dry, Dull Convex Regular edge	+	-
<i>Bacillus megaterium</i> ssp. BCM 9	<i>Taxus hunnewelliana</i>	+	Rod	Gray- Opaque Dry-Dull Convex Irregular edge	Cream- Opaque Glossy Slightly convex Irregular edge	+	-
<i>Curtobacterium</i> sp. BCM 5	<i>Taxus brevifolia</i>	+	Rod	2 days to grow Cream Semi-translucent Glossy-Flat Regular edge	2 days to grow Yellow Semi-translucent Glossy-Flat Regular edge	+	-
<i>Sphingomonas</i> sp. BCM 7	<i>Taxus hunnewelliana</i>	-	Rod	No growth	3 days to grow Orange-Opaque Glossy-Convex Regular edge	+	-

5

b) Identification of the genus of taxanes and
paclitaxel producing microorganisms

The genus of each taxanes and paclitaxel producing bacteria was determined by sequencing the 16S

rRNA genes. Genomic DNA of each strain was used as template for PCR (Polymerase Chain Reaction). Primers based on conserved regions at the beginning and the end of the 16S rRNA gene, SSU-27 (5'-AGAGTTTGATCMTGGCTCAG-3'; SEQ ID NO:12), and SSU-1 492 (5'-TACGGYTACCTTGTTACGACTT-3'; SEQ ID NO:13), were used to amplify a portion of the 16S gene. The amplicons were purified with the "PCR purification kit" (sold by Qiagen) and sequenced using the ABI Prism System. Sequence analysis was performed using GCG software package (Genetics Computer Group Inc., Madison, WI).

Fig. 8A shows the almost complete sequence of the 16S rRNA gene of *Sphingomonas taxi*. Since this strain has unique biosynthetic capacities and more than 3% sequence difference with the 16S rRNA genes of other known species of *Sphingomonas*, we created a new species and named it *taxi* on the behalf of its isolation source. Fig. 8B shows the almost complete sequence of the 16S rRNA gene of *Bacillus cereus* ssp. *taxi*. Since this bacterium possesses unique metabolic capacities, and in order to differentiate this species from other known *Bacillus cereus*, we identified it by subspecies name *taxi* also on the behalf of its isolation source. In Figs. 8C to 8L, we show partial sequences of the 16S rRNA genes of other taxanes and/or paclitaxel producing microorganisms.

Consequently, in accordance with the present invention, a plurality of bacteria isolated from different species of *Taxus* can be used for the mass production of paclitaxel and other taxanes. Based on the analysis of partial 16S rRNA gene sequences, and morphological and biochemical characteristics, we assigned

the following genera, species, and subspecies or strain names to our paclitaxel and taxanes producing bacterial isolates; *Sphingomonas taxi*, *Bacillus cereus* ssp. *taxi*, *Bacillus megaterium* ssp. *taxi*, *Pantoea* sp. BCM 1, *Pantoea* sp. BCM 2, *Pantoea* sp. BCM 3, *Bacillus cereus* ssp. BCM 4, *Bacillus subtilis* ssp. *taxi*, *Bacillus megaterium* ssp. BCM 9, *Curtobacterium* sp. BCM 5 and *Sphingomonas* sp. BCM 7.

10 **Biotransformation of taxanes**

a) **Preparation of an aqueous extract of *Taxus canadensis***

Fresh cuttings of needles and small twigs (10 g) of a sample of *Taxus canadensis* are homogenized in 100 ml of distilled water. The solution is then centrifuged at 7 000 rpm and the clear supernatant sterilized by filtration on a 0,22 μ m filter. The solution is kept frozen at -20°C until utilization.

20 b) **Biotransformation of taxanes by taxanes and paclitaxel producing bacteria**

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus canadensis*. This resulting supplemented medium is then inoculated with a thawed vial of a pure culture of one of our strain and incubated at 30°C with constant shaking for a time sufficient to allow biotransformation of pro-taxanes.

The culture is then centrifuged and the remaining supernatant extracted with one volume of methylene chloride or ethyl acetate. After appropriate shaking, the organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in

50 ml of methylene chloride or ethyl acetate, and 50 ml of distilled water. After appropriate shaking, each fraction was collected and dried under reduced pressure. Each residue is dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C until analysis.

Samples were analyzed on HPLC using method no. 2. Fig. 11 shows the evolution of two taxanes in A) the sterile culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* shaken at 150 rpm and incubated at 30°C, and in B) the supernatant of *Sphingomonas taxi* cultured in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* shaken at 150 rpm and incubated at 30°C. This figure clearly illustrates that in the supernatant of *Sphingomonas taxi*, the diminution of the taxane eluted at 12 minutes corresponds to the proportional elevation of the taxane eluted at 24 minutes, proving the capacity of *Sphingomonas taxi* to biotransform taxanes.

In addition, Fig. 12 compares the HPLC chromatogram of the organic extract of the culture supernatant of *S. taxi* incubated 24, 48 and 72 hours in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*. This Fig. 12 clearly illustrates the production of pro-taxanes. The ultraviolet spectrum of one of these pro-taxanes is illustrated in Fig. 14A. Fig. 14A compares the UV spectrum of the new biotransformed taxane produced by *S. taxi* with taxanes from the aqueous extract of *Taxus canadensis*.

Mutagenesis of taxanes and paclitaxel producing bacteria

Typically, 20 ml of the culture medium TA-1 with 200 µg/ml of daunorubicin (purchased from Rhône-Poulenc) were inoculated with 500 µl of an overnight culture. The resulting broth was incubated at 200 rpm at 30°C for 2 days. After this time 10 ml of the broth are added to 10 ml of fresh medium containing 200 µg/ml of daunorubicin and incubated as described above. The preceding step is repeated as necessary to obtain mutated bacteria. Those mutants were further isolated on the solid culture medium TA-1 (composition as follows).

Solid culture medium TA-1

Ingredient	amount
glucose	5 g
tryptone	20 g
yeast extract	5 g
NaCl	0.5 g
agar	15 g
H ₂ O	1 L

15

Biotransformation of taxanes by mutated strains

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus canadensis*. This resulting supplemented medium is then inoculated with a thawed vial of a pure culture of one of our strain and incubated at 30°C with constant shaking for a time sufficient to allow biotransformation of pro-taxanes.

The culture is then centrifuged and the remaining supernatant extracted with one volume of methylene

25

chloride or ethyl acetate. After appropriate shaking, the organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in 50 ml of methylene chloride or ethyl acetate, and 50 ml of distilled water. After appropriate shaking, each fraction was collected and dried under reduced pressure. Each residue is dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C until analysis.

10 Samples were analyzed on HPLC using method no. 2. Fig. 13 shows HPLC chromatograms of *S. taxi*, *S. taxi* D200 and *S. taxi* D201 incubated the same time (48 hours) in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*. All 15 cultures had comparable cell density. This figure clearly illustrates the improved yields of biotransformation by the mutated strains *S. taxi* D200 and *S. taxi* D201. In Figs. 14B and 14C the characteristic ultra-violet spectrum of the new pro-taxanes, produced by the 20 mutated strains *S. taxi* D200 and *S. taxi* D201, are compared with the UV spectrum of two taxanes from *Taxus canadensis*.

The present invention will be more readily understood by referring to the following examples which 25 are given to illustrate the invention rather to limit its scope.

EXAMPLE I

Mass production of paclitaxel using *Sphingomonas taxi*

A colony of a pure culture of *Sphingomonas taxi* 30 is used to inoculate 5 ml of S-7 culture medium. The broth is incubated 2-3 days with constant shaking (90 rpm) at 22°C. This 5 ml is then transferred into 5

liters of the same culture medium. The resulting broth is incubated as described above in aerobic conditions.

After 4-5 days of incubation, or after the maximum cell density is reached, the cell pellet is separated by centrifugation. Hydrophobic compounds are then extracted from the supernatant by partition with one volume of dichloromethane. Each organic fraction is evaporated to dryness and, the residue is solubilized in a minimal amount of HPLC grade methanol, typically 500 μ l to 1 ml.

Paclitaxel and taxanes are further purified by HPLC on a phenyl column using HPLC method no. 1. Typically, up to 400 μ l of the methanolic solution are injected and fractions of 0,5 ml to 1 ml are collected. Fractions containing paclitaxel or taxanes are evaporated to dryness.

Using this method, from 200 ng to 1 μ g of paclitaxel per liter of culture medium were purified.

20

EXAMPLE II

Mass production of taxanes and paclitaxel using *Bacillus cereus* ssp. *taxi*

A thawed vial of a pure dense cell suspension of *Bacillus cereus* ssp. *taxi* is used to inoculate 500 ml of the defined medium for *Bacillus*. The broth is incubated 1 to 3 days with constant shaking (150 rpm) at 30°C. The cell pellet is then separated from the supernatant by centrifugation. Hydrophobic substances are extracted from the supernatant by an extraction with one volume of dichloromethane. The organic fraction is evaporated to dryness under reduced pressure,

and residues resolubilized in a minimal amount of HPLC grade methanol.

Taxanes and paclitaxel are further purified on HPLC using method no. 2. Using this method, from 0,2 to 10 µg of paclitaxel can be produced, and from 0,2 to 15 µg of taxanes, including the specific bacterial taxane illustrated in Fig. 13B, can also be produced.

EXAMPLE III

10 Mass production of taxanes and paclitaxel using *Bacillus megaterium* ssp. *taxi*

A thawed vial of a pure dense cell suspension of *Bacillus megaterium* ssp. *taxi* is used to inoculate 500 ml of the S-7 culture medium. The broth is incubated 1 to 3 days with constant shaking (150 rpm) at 30°C. The cell pellet is then separated from the supernatant by centrifugation. Hydrophobic substances are extracted from the supernatant by an extraction with one volume of dichloromethane. The organic fraction is evaporated to dryness under reduced pressure, and residues resolubilized in a minimal amount of HPLC grade methanol.

Taxanes and paclitaxel are further purified on HPLC using method no. 2. Using this method, from 1 to 12 µg of paclitaxel can be produced, and from 1 to 15 µg of taxanes, including the specific bacterial taxane illustrated in Fig. 13B, can also be produced.

EXAMPLE IV

30 Biotransformation of pro-taxanes by *Sphingomonas taxi*

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus*

canadensis. This resulting supplemented medium is then inoculated with a thawed vial of a pure culture of one of *Sphingomonas taxi* and incubated at 30°C with constant shaking for 24 to 96 hours.

5 The culture is then centrifuged and the remaining supernatant extracted with one volume of methylene chloride. After appropriate shaking, the organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in 50 ml of methylene
10 chloride and 50 ml of distilled water. After appropriate shaking, the organic fraction is collected and dried under reduced pressure. The residue is dissolved in 500 µl of HPLC grade methanol and 100 µl of the
15 methanolic solution are analyzed on HPLC using method no. 2 and compared to the resulting chromatogram of the organic extract of the growth-supporting nutrient medium supplemented with and aqueous extract of *Taxus canadensis* 1% v/v shaken the same time.

20 As illustrated in Figs. 11, 12 and 14A, *Sphingomonas taxi* is able to biotransform taxanes into new pro-taxanes.

EXAMPLE V

Mutagenesis of *Sphingomonas taxi*

25 20 ml of the culture medium TA-1 with 200 µg/ml of daunorubicin (purchased from Rhône-Poulenc) were inoculated with 500 µl of an overnight culture of *Sphingomonas taxi*. The resulting broth was incubated at 200 rpm at 30°C for 2 days. After this time 10 ml
30 of the broth are added to 10 ml of fresh medium containing 200 µg/ml of daunorubicin and incubated as described above. The preceding step is repeated as necessary to obtain mutated bacteria. Those mutants were further isolated on the solid culture medium TA-1. Two

new mutated strains were obtained named *Sphingomonas taxi* D200 and *Sphingomonas taxi* D201.

EXAMPLE VI

5 Biotransformation of taxanes by *Sphingomonas taxi* D200 and *Sphingomonas taxi* D201

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus canadensis*. This resulting supplemented medium is then
10 inoculated with a thawed vial of a pure culture of one of our mutated strain and incubated at 30°C at 150 rpm. Cultures were stopped after 24, 48 and 72 hours of incubation.

Cultures were then centrifuged and the remaining
15 supernatants extracted with one volume of ethyl acetate. After appropriate shaking, the organic fractions were evaporated to dryness under reduced pressure. Residues were then resolubilized in 50 ml of ethyl acetate. After appropriate shaking, fractions
20 were collected and dried under reduced pressure. Each residues were dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C until analysis.

Samples were analyzed on HPLC using method no.
25 2. Fig. 13 shows HPLC chromatograms of *S. taxi*, *S. taxi* D200 and *S. taxi* D201 incubated the same time (48 hours) in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*. All cultures had comparable cell densities. This figure
30 clearly illustrates the improved yields of biotransformation by the mutated strains *S. taxi* D200 and *S. taxi* D201. In Fig. 14B the characteristic ultraviolet spec-

trum of the new pro-taxanes produced by *S. taxi* D200 is compared with the UV spectrum of two taxanes from *Taxus canadensis*. Fig. 14C compares the UV spectrum of the new biotransformed taxane produce by *S. taxi* D201 with
5 taxanes from the aqueous extract of *Taxus canadensis*.

While the invention has been described in connection with specific embodiments thereof, it will be understood that is capable of further modifications and this application is intended to cover any variations,
10 uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as many be applied to
15 the essential features hereinbefore set forth, and as follows in the scope of the appended claims.



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: 301-231-5519 or 231-5532 • FAX: 301-816-4344

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

BCM Developpement Inc.
Attn: Nathalie Landry
125 rue Dalhousie, suite 218
Quebec Canada G1K 4C5

REC'D 30 MAR 1999

WIPO PCT

Deposited on Behalf of: BCM Developpement

Identification Reference by Depositor:

ATCC Designation

<i>Bacillus cereus</i> ssp. <i>taxi</i>	202061
<i>Bacillus megaterium</i> ssp. <i>taxi</i>	202062
<i>Curtobacterium</i> sp. BCM5	202063
<i>Pantoea</i> sp. BCM2	202064
<i>Bacillus megaterium</i> BCM9	202065
<i>Bacillus cereus</i> BCM4	202066

The deposits were accompanied by: ☐ a scientific description ☒ a proposed taxonomic description indicated above. The deposits were received December 12, 1997 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: ☒ We will not inform you of requests for the strains.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested December 18, 1997. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Barbara M. Hailey
Barbara M. Hailey, Administrator, Patent Depository

Date: December 18, 1997

cc: France Cote



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: 301-231-5519 or 231-5532 • FAX: 301-816-4344

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

BCM Developpement Inc.
Attn: Nathalie Landry
125 rue Dalhousie, suite 218
Quebec Canada G1K 4C5

Deposited on Behalf of: BCM Developpement

Identification Reference by Depositor:

ATCC Designation

<i>Sphingomonas taxi</i> D201	202067
<i>Sphingomonas taxi</i> D200	202068
<i>Sphingomonas</i> sp. BCM7	202069
<i>Pantoea</i> sp. BCM3	202070
<i>Pantoea</i> sp. BCM1	202071
<i>Bacillus subtilis</i> ssp. taxi	202072

The deposits were accompanied by: ☐ a scientific description ☒ a proposed taxonomic description indicated above. The deposits were received December 12, 1997 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: ☒ We will not inform you of requests for the strains.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested December 18, 1997. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Barbara M. Hailey
Barbara M. Hailey, Administrator, Patent Depository

Date: December 18, 1997

cc: France Cote

WHAT IS CLAIMED IS:

1. A process for producing a taxane, which comprises the steps of:

- a) culturing at least one ~~bacteria~~ bacteria isolated from plant species of *Taxus* in growth-supporting nutrient medium capable of promoting growth and reproduction of said bacteria, and wherein said culturing is effected for a time sufficient to allow production of a taxane; and
- b) recovering a taxane from said bacteria or medium of step a).


2. The process of claim 1, wherein the plant species of *Taxus* is of the species selected from the group consisting of but not limited to *Taxus canadensis*, *T. brevifolia*, *T. baccata*, *T. hunnewelliana* or *T. cuspidata*.

3. The process of claim 1, wherein said bacteria is of the genus selected from the group consisting of *Sphingomonas*, *Bacillus*, *Pantoea*, and *Curtobacterium*.

4. The process of claim 1, wherein said taxane produced is paclitaxel.

5. The process of claim 1, wherein said taxane is selected from the group consisting of paclitaxel, 10-deacetylcephalomannine, 7-epitaxol, 10-deacetyl-7-epitaxol, 7-epicephalomannine, baccatin III, 10-deacetyl-baccatin III, cephalomannine, 7-epibaccatin III, 7-

xylosyltaxol, 7-xylosyl-cephalomannine, taxagifine, δ -benzoyloxy taxagifine, 9-acetyloxy taxusin, 9-hydroxy taxusin, taxane Ia, taxane Ib, taxane Ic, taxane Id and any taxane corresponding to Formula I:



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1.

Table 1

Compound	R ₁ ⁽¹⁾	R ₂	R ₃	R ₄	R ₅	R ₆ ⁽²⁾	R ₇ ⁽³⁾	R ₈ R ₉ R ₁₀ ⁽⁴⁾	R ₁₁	R ₁₂ ⁽⁵⁾	R ₁₃	R ₁₄	R ₁₅ ⁽⁶⁾	R ₁₆
1) paclitaxel	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
2) 10-deacetyl- cephalomannine	ceph	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
3) 7-epitaxol	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
4) 10-deacetyl-7- epitaxol	tax	CH ₃	H	β-OH	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
5) 7-epi- cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
6) baccatin III	α-OH	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
7) 10-deacetyl baccatin III	α-OH	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
8) cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
9) 10-deacetyl taxol	tax	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
10) 7-xylosyl taxol	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-xylosyl	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
11) 7-xylosyl- cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-xylosyl	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
12) taxagifine	=O	α-CH ₃	β-OH	β-acetyloxy	α-acetyloxy	β-CH ₃	β-acetyloxy	H	α-cinnamoyloxy	methylene (=CH ₂)	α-acetyloxy	β-H	H	cydo α-CH ₃
13) 8-benzoyloxy- taxagifine	=O	α-CH ₃	β-OH	β-acetyloxy	α-acetyloxy	β-benzoyl- oxymethyl	β-acetyloxy	H	α-cinnamoyloxy	methylene (=CH ₂)	α-acetyloxy	β-H	H	cydo α-CH ₃
14) 9-acetyloxy- taxusin	α-acetyloxy	CH ₃	H	β-acetyloxy	α-acetyloxy	β-CH ₃	H	H	α-acetyloxy	methylene (=CH ₂)	H	H	H	CH ₃
15) 9-hydroxy-taxusin	α-acetyloxy	CH ₃	H	β-acetyloxy	α-OH	β-CH ₃	H	H	α-acetyloxy	methylene (=CH ₂)	H	H	H	CH ₃
16) taxane Ia	tax	CH ₃	H	=O	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
17) taxane Ib	taxsub	CH ₃	H	=O	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
18) taxane Ic	taxsub	CH ₃	H	=O	=O	β-CH ₃	α-acetyloxy	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃
19) taxane Id	α-acetyloxy	CH ₃	H	β-acetyloxy	α-acetyloxy	β-CH ₃	β-acetyloxy	H	α-OH	epoxide	α-acetyloxy	β-OH	H	CH ₃
20) 7-epibaccatin III	α-OH	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃

6. A bacterial taxane having the characterizing ultraviolet spectrum and the specific retention time shown in Fig. 13, and the EI spectrum shown in Fig. 14A.

7. The process of claim 1, wherein the taxane produced having the characterizing ultraviolet spectrum and the specific retention time shown in Fig. 13, and the EI spectrum shown in Fig. 14A.

8. The process of claim 1, wherein the bacteria is *Bacillus cereus* ssp. *taxi*.

9. The process of claim 1, wherein the bacteria is *Bacillus megaterium* ssp. *taxi*.

10. The process of claim 1, wherein the bacteria is *Pantoea* sp. BCM 1.

11. The process of claim 1, wherein the bacteria is *Pantoea* sp. BCM 2.

12. The process of claim 1, wherein the bacteria is *Pantoea* sp. BCM 3.

13. The process of claim 1, wherein the bacteria is *Bacillus cereus* ssp. BCM 4.

14. The process of claim 1, wherein the bacteria is *Bacillus subtilis* ssp. *taxi*.

15. The process of claim 1, wherein the bacteria is *Bacillus megaterium* ssp. BCM 9.


16. The process of claim 1, wherein the bacteria is *Curtobacterium* sp. BCM 5.

17. The process of claim 1, wherein said growth-supporting nutrient medium include carbon sources, nitrogen sources, amino acids, vitamins and minerals.

18. A process for producing biotransformed taxanes, which comprises the steps of:

- a) culturing at least one bacteria isolated from plant species of *Taxus* in growth-supporting nutrient medium supplemented with pro-taxanes, and wherein said culturing is effected for a time sufficient to allow the biotransformation of pro-taxanes into taxanes; and
- b) recovering at least one from said bacteria or medium of step a).

19. The process of claim 18, wherein said taxane is selected from the group consisting of paclitaxel, 10-deacetylcephalomannine, 7-epitaxol, 10-deacetyl-7-epitaxol, 7-epicephalomannine, baccatin III, 10-deacetyl baccatin III, cephalomannine, 7-epibaccatin III, 7-xylosyltaxol, 7-xylosyl-cephalomannine, taxagifine, 8-benzoyloxy taxagifine, 9-acetyloxy taxusin, 9-hydroxy taxusin, taxane Ia, taxane Ib, taxane Ic, taxane Id and any taxane corresponding to Formula I :



wherein $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}$ are defined in Table 1,

Table 1

Compound	R ₁ ⁽¹⁾	R ₂	R ₃	R ₄	R ₅	R ₆ ⁽¹⁾	R ₇ ⁽²⁾	R ₈ R ₉ ⁽³⁾	R ₁₀ ⁽⁴⁾	R ₁₁	R ₁₂ ⁽⁵⁾	R ₁₃	R ₁₄	R ₁₅ ⁽⁶⁾	R ₁₆
1) paditaxel	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
2) 10-deacetyl- cephalomannine	ceph	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
3) 7-epitaxol	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
4) 10-deacetyl-7- epitaxol	tax	CH ₃	H	β-OH	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
5) 7-epi- cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
6) baccatin III	α-OH	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
7) 10-deacetyl baccatin III	α-OH	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
8) cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
9) 10-deacetyl taxol	tax	CH ₃	H	β-OH	=O	β-CH ₃	β-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
10) 7-xylosyl taxol	tax	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-xylosyl	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
11) 7-xylosyl- cephalomannine	ceph	CH ₃	H	β-acetyloxy	=O	β-CH ₃	β-xylosyl	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
12) taxagifine	=O	α-CH ₃	β-OH	β-acetyloxy	α-acetyloxy	β-CH ₃	β-acetyloxy	H	α-cinnamoyloxy	methylene (=CH ₂)	α-acetyloxy	β-H	H	cyclo	α-CH ₃
13) 8-benzoyloxy- taxagifine	=O	α-CH ₃	β-OH	β-acetyloxy	α-acetyloxy	β-benzoyl- oxymethyl	β-acetyloxy	H	α-cinnamoyloxy	methylene (=CH ₂)	α-acetyloxy	β-H	H	cyclo	α-CH ₃
14) 9-acetyloxy- taxusin	α-acetyloxy	CH ₃	H	β-acetyloxy	α-acetyloxy	β-CH ₃	H	H	α-acetyloxy	methylene (=CH ₂)	H	H	H	CH ₃	CH ₃
15) 9-hydroxy-taxusin	α-acetyloxy	CH ₃	H	β-acetyloxy	α-OH	β-CH ₃	H	H	α-acetyloxy	methylene (=CH ₂)	H	H	H	CH ₃	CH ₃
16) taxane Ia	tax	CH ₃	H	=O	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
17) taxane Ib	taxsub	CH ₃	H	=O	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
18) taxane Ic	taxsub	CH ₃	H	=O	=O	β-CH ₃	α-acetyloxy	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃
19) taxane Id	α-acetyloxy	CH ₃	H	β-acetyloxy	α-acetyloxy	β-CH ₃	β-acetyloxy	H	α-OH	epoxide	α-acetyloxy	β-OH	H	CH ₃	CH ₃
20) 7-epibaccatin III	α-OH	CH ₃	H	β-acetyloxy	=O	β-CH ₃	α-OH	H	oxetane	α-acetyloxy	α-benzoyloxy	β-OH	H	CH ₃	CH ₃

20. The process of claim 19, wherein said pro-taxanes are isolated from any species of *Taxus*.

21. The process of claim 19, wherein said pro-taxanes are isolated from *Taxus canadensis*.

22. The process of claim 19, wherein the bacteria is *Bacillus cereus* ssp. *taxi*.

23. The process of claim 19, wherein the bacteria is *Bacillus megaterium* ssp. *taxi*.

24. The process of claim 19, wherein the bacteria is *Pantoea* sp. BCM 1.

25. The process of claim 19, wherein the bacteria is *Pantoea* sp. BCM 2.

26. The process of claim 19, wherein the bacteria is *Pantoea* sp. BCM 3.

27. The process of claim 19, wherein the bacteria is *Bacillus cereus* ssp. BCM 4.

28. The process of claim 19, wherein the bacteria is *Bacillus subtilis* ssp. *taxi*.

29. The process of claim 19, wherein the bacteria is *Bacillus megaterium* ssp. BCM 9.

30. The process of claim 19, wherein the bacteria is *Curtobacterium* sp. BCM 5.

31. A process for isolating taxanes and paclitaxel producing bacteria from a yew tree, which comprises the steps of:

- a) disinfecting the surface of a yew tree plant part with a suitable disinfectant;
- b) cutting and disrupting the disinfected plant part;
- c) leaching out bacteria with an appropriate solvent from the part of step c);
- d) culturing said leached bacteria on a solid growth-supporting nutrient medium for a time sufficient to allow formation of visible isolated colonies; and
- e) screening said isolated colonies for production of taxanes and paclitaxel.

32. The process of claim 31, wherein the disinfectant used is ethanol at concentration varying from 35% to 99%.

33. The process of claim 31, wherein the solvent to leach out bacteria is water.

34. The process of claim 31, wherein the solid growth-supporting nutrient medium for isolating colonies is selected from the group consisting of R2A agar (Difco) and Sabouraud (Difco).

35. The process of claim 31, wherein screening of isolated bacteria for taxanes and paclitaxel production comprises the steps of:

- a) culturing said isolated bacteria in 500 ml of a growth-supporting liquid nutrient medium at temperature ranging from 20 to 35°C with constant shaking until sufficient growth is achieved;
- b) obtaining the culture medium supernatant or the cells and extracting it with appropriate organic solvents selected from methylene chloride and ethyl acetate;
- c) analyzing said organic extracts by a method suitable for detection of taxanes and paclitaxel.

36. The process of claim 35, wherein the method to detect taxanes and paclitaxel in extracts uses HPLC retention times on a hydrophobic chromatographic matrix and ultraviolet spectra to identify taxanes and paclitaxel in comparison with standards.

37. The process of claim 35, wherein the method to detect taxanes and paclitaxel in extracts uses cytotoxicity on cancer cell lines.

38. The process of claim 35, wherein the method to detect taxanes in extracts uses mass spectrometry to identify paclitaxel and taxanes based on molecular weights fragments and/or total molecule.

39. The process of claim 35, wherein the method to detect taxanes and paclitaxel in extracts uses antibodies raised against taxanes and paclitaxel.

40. The process of claim 35, wherein the method to

detect taxanes and paclitaxel uses an *in vitro* assay monitoring interaction of taxanes with tubulin.

41. A process for improving biotransformation of pro-taxanes into taxanes and paclitaxel by taxanes and paclitaxel-producing bacteria comprising the steps of:

- a) culturing bacteria in the presence of a mutagenic agent for a time sufficient to allow mutagenesis; and
- b) selecting said mutants by a change of the phenotype which results in an increased biotransformation of pro-taxanes into taxanes and paclitaxel.

42. The process of claim 41, wherein the mutagenic agent is a chemical agent.

43. The process of claim 41, wherein the chemical agent is daunorubicin or nitrosoguanidine.

44. The process of claim 41, wherein the mutagenic agent is a physical agent selected from gamma radiation or ultraviolet.

45. The process of claim 41, wherein the mutagenic agent is a biological agent.

46. The process of claim 45, wherein the biological agent is a transposon.

47. A method of bacterial biotransformation of pro-taxanes into taxanes and paclitaxel thereof which com-

prises the steps of:

- a) incubating the mutated bacteria obtained according to the process of claim 41 in a nutrient medium, and wherein said incubation is effected in the presence of pro-taxanes for a time sufficient to allow production of taxanes and paclitaxel; and
- b) isolating said produced taxanes and paclitaxel thereof from said culturing medium of step a).

48. The process of claim 43, wherein the bacteria used is *Sphingomonas taxi* D200.

49. The process of claim 43, wherein the bacteria used is *Sphingomonas taxi* D201.

50. The process of claim 43, wherein the mutated bacterium is isolated from a *Taxus* species and is of the genus of *Sphingomonas*, *Bacillus*, *Pantoea* or *Curtobacterium*.

51. A biologically pure culture of a bacteria of genus *Sphingomonas*, *Bacillus*, *Pantoea* or *Curtobacterium*, which is isolated from *Taxus canadensis*, and wherein said bacteria is characterized by the production of taxane and paclitaxel in a culture media.

52. The biologically pure culture of the bacteria of claim 51, which is *Sphingomonas taxi*, *Bacillus cereus* ssp. *taxi*, *Bacillus megaterium* ssp. *taxi*, *Pantoea* sp. BCM 1, *Pantoea* sp. BCM 2, *Pantoea* sp. BCM 3, *Bacillus cereus* ssp. BCM 4, *Bacillus subtilis* ssp. *taxi*, *Bacil-*

lus megaterium ssp. BCM 9 and *Curtobacterium* sp. BCM 5.

53. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus *Sphingomonas*, belonging to the alpha subdivision of Proteobacteria.


54. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus *Bacillus* belonging to the low G+C Gram positive bacteria.

55. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus *Pantoea*, belonging to the gamma subdivision of Proteobacteria.


56. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus is isolated from a *Taxus* species and is of the genus *Curtobacterium*, belonging to the Actinomycetes order of the firmicutes.

57. The biologically pure culture of the bacteria of claim 51, wherein said bacteria is mutated and is *Sphingomonas taxi* D200 or *Sphingomonas taxi* D201.


1/26





2/26

FIG. 1B



3/26

FIG. 2A


4/26

FIG. 2BFIG. 2C


5/26

FIG. 3AFIG. 3B

6/26





4A



4B

7/26



Spectral Table


#	Retention Time	Source	Spectrum Name	Baseline Correct	Searchable	Traceable
1	35.820	B.B. F2 def di		On	Yes	Yes
2	35.703	13-mix stds	7-epi-10-deacetylaxol	On	Yes	Yes



Spectral Table

#	Start Wvln	End Wvln	Resolution	Smooth	Derivative	Spline	Lambda Max	Maximum Absorbance
1	200	350	2.4	None	None	Off	200.6	0.00501
2	200	350	2.4	None	None	Off	200.6	0.42673

FIG. 5B

8/26

FIG. 6



10/26

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1020
1080
1140
1200
1260
1320
1380
1440
1500
1556

ATGATTACGC CAAGCTATTT AGGTGACACT ATAGAATACT CAAGCTATGC ATCCAACGCG
TTGGGAGCTC TCCCATATGG TCGACCTGCA GCGGCCGCA CTAGTGATTA GAGTTTGATC
CTGGCTCAGA ACGAACGCTG GCGGCATGCC TAACACATGC AAGTCGAACG AGATCTTCGG
ATCTAGTGGC GCACGGGTGC GTAACGCGTG GGAATCTGCC CTTTGGTTCG GAATAACAGT
TGGAACGAC TGCTAATACC GGATGATGAC GTAAGTCCAA AGATTATCG CCAGAGGATG
AGCCCGCGTA GGATTAGCTA GTTGGTGTGG TAAGAGCGCA CCAAGGCGAC GATCCTTAGC
TGGTCTGAGA GGATGATCAG CCACACTGGG ACTGAGACAC GGCCAGACT CCTACGGGAG
GCAGCAGTGG GGAATATTGG ACAATGGGCG AAAGCCTGAT CCAGCAATGC CGCGTGAGTT
GATGAAAGCC TTAGGTTGTT AAAGCTCTTT TACCCGGGAA TGATAATGAC AGTACCGGGA
GAATAAGCTC CGGCTAACTC CGTGCCAGCA GCCCGGGTAA TACGGAAGGA GCTAGCGTTG
TTCGGAATTA CTGGCGGTAA AGCGCACGTA GCGGCTTTG TAAGTTAGAG GTGAAAGCCT
GGAGCTCAAC TCCAGAATTG CCTTTAAGAC TGCATCGCTT GAATCCAGGA GAGTGAGTG
GAATTCCGAG TGTAGAGGTG AAATTCGTAG ATATTCGGAA GAACACCACT GCGGAAGCGG
GCTCACTGGA CTGGTATTGA CGCTGAGGTG CGAAAGCGTG GGGAGCAAAC AGGATTAGAT
ACCCCTGGTAG TCCACGCCGT AACGATGAT AACTAGCTGT CCGGGGACTT GGTCTTTGGG
TGGCGCAGCT AACGCATTAA GTTATCCGCC TGGGGAGTAC GSCCGCAAGG TTAAAACTCA
AATGAATTGA CGGGGCCTG CACAAGCGGT GGAGCATGTG GTTTAATTCTG AAGCAACGCG
CAGAACCTTA CCAGCGTTTG ACATGTCCGG ACGATTCTTG GAGACAGATC TCTTCCCTTC
GGGACTGGA ACGAGGTGC TGCATGGCTG TCGTCAGCTC GTGTCGTGAG ATGTTGGGTT
AAGTCCCGCA ACGAGCGCAA CCTCGCCTT TAGTTACCAT CATTTAGTTG GGGACTCTAA
AGGAACCGCC GGTGATAAGC CGGAGGAAGG TGGGATGAC GTCAAGTCCT CATGGCCCTT
ACCGCTGGG CTACACACGT GCTACAATGG CGGTGACAGT GGGCAGCAAA CTCGCGAGAG
TGCCTAATC TCCAAAAGCC GTCTCAGTTC GGATTGTTCT CTGCAACTCG AGAGCATGAA
GGCGGAATCG CTAGTAATCG CGGATCAGCA TGCCCGCGTG AATACGTTCC CAGGCCTTGT
ACACACCGCC CGTCACACCA TGGGAGTTGG GTTCACCCGA AGCGTTGCG CTAACCTCGTA
AGAGAGGCAG GCGACCACGG TGGGCTTAGC GACTGGGGTG AAGTCGTAAAC AAGGTA

11/26

60 AGAGTTTGAT CATGGCTCAG GATGAACGCT GGCGGCGTGC CTAATACATG CAAGTCGAGC
120 GAATGGATTA AGAGCTTGCT CTTATGAAGT TAGCGGCGGA CCGGTGAGTA ACACGTGGGT
180 AACCTACCCA TAAGACTGGG ATAACCTCGG GAAACCGGGG CTAATACCGG ATAATATTTT
240 GAACTGCATA GTTCGAAATT GAAAGCGGC GTTCGGCTGTC ACTTATGGAT GGACCCGCGT
300 CGCATTAGCT AGTTGGTGAG GTAAACGGCTC ACCAAGCGA CGATGCGTAG CCGACCTGAG
360 AGGCTGATCG GCCACACTGG GACTGAGACA CGGCCAGAC TCCTACGGA GGCAGCAGTA
420 GGGAACTTTC CGCAATGGAC GAAAGTCTGA CGGAGCAACG CCGCGTGAGT GATGAAGGCT
480 TTCGGGTCGT AAAACTCTGT TGTTAGGGAA GAACAAGTGC TAGTTGAATA AGCTGGCAC
540 TTGACGGTAC CTAACCCAGAA AGCCACGGCT AACTACGTGC CAGCAGCCCG CGGTAATACG
600 TAGGTGGCAA GCGTTATCCG GAATTATTGG GCGTAAAGCG CCGCAGGTG GTTCTTAAG
660 TCTGATGTGA AAGCCACCGG CTCAACCGTG GAGGTCATT GGAACCTGGG AGACTTGAGT
720 GCAGAAGAGG AAAGTGAAT TCCATGTGTA GCGTGAAAT GCGTAGAGAT ATGGAGGAAC
780 ACCAGTGGCG AAGCGACTT TCTGCTCTGT AACTGACACT GAGCGCGAA AGCGTGGGA
840 GCAAAACAGGA TTAGATACCC TGGTAGTCCA CGCCGTAAAC GATGAGTGCT AAGTGTTAGA
900 GGGTTTCCGC CCTTTAGTGC TGAAGTTAAC GCATTAAGCA CTCCGCCCTGG GGAGTACGGC
960 CGCAAGGCTG AAACCTCAAAG GAATTGACGG GGGCCCGCAC AAGCGGTGA GCATGTGGTT
1020 TAATTGGAAG CAACGCGAAG AACCTTACCA GGTCTTGACA TCCTCTGAAA ACTCTAGAGA
1080 TAGAGCTTCT CCTTCGGGAG CAGAGTGACA GGTGGTGAT GGTGTCTGTC AGCTCGTGT
1140 GTGAGATGTT GGGTTAAGTC CCGCAACGAG CCGAACCTT GATCTTAGTT GCCATCATTA
1200 AGTTGGGCAC TCTAAGGTGA CTGCCGGTGA CAAACCGGAG GAAGGTGGG ATGACGTCAA
1260 ATCATCATGC CCCTTATGAC CTGGGCTACA CACGTGCCAC AATGGACCGT ACAAGAGCT
1320 GCAAGACCGC GAGGTGGAGC TAATCTCATA AAACCGTTCT CAGTTCGGAT TGTAGGCTGC
1380 AACTCGCCTA CATGAAGCTG GAATCGCTAG TAATCGCGGA TCAGCATGCC GCGGTGAATA
1440 CGTTCCTGGG CCTTGTACAC ACCGCCGCTC ACACCCAGAG AGTTTGTAA ACCTGAAAGTC
1500 GGTGGGGTAA CCTTTATGGA GCCAGCCGCC TAAGGTGGGA CAGATGATTG GGGTGAAGTC
1512 GTAACAAGGT AA

SUBSTITUTE SHEET (RULE 26)

BB

12/26

60 AGAGTTTGAT CCTGGCTCAG GATGAACGCT GCGGCGGTGC CTAATACATG CAAGTCGAGC
120 GAACTGATTA GAAGCTTGCT TCTATGACGT TAGCGGCGGA CCGGTGAGTA ACACGTGGGC
180 AACCTGCCCTG TAAGACTGGG ATAACCTCGG GAAACCGAAG CTAATACCGG ATAGGATCTT
240 CTCCTTCATG GGGATGATT GAAAGATGGT TTCGGCTATC ACTTACAGAT GGGCCCGCGG
300 TGCATTAGCT AGTTGGTGAG GTAAACGGCTC ACCAAGGCAA CGATGCATAG CCGACCTGAG
360 AGGGTGATCG GCCACACTGG GACTGAGACA CCGCCCAAAC TCCTACGGGA GGCAGCAGTA
420 GCGAATCTTC CGCAATGGAC GAAAGTCTGA CCGAGCAAAC CCGCGTGAGT GATGAAGGCT
480 TTCGGGTCCT AAAACTCTGT TGTnGGGAA GAACAATACT CAGAGTAACT GCTTGTTCCT
540 TGACGGTACC TAACCAGAAA GCCACGGCTA ACTACTTTCC AGCAGCCCGG GTAATACnTA
600 TGTnGGCAAG CGTTATCCGG AATTATnGGG GCGTTAAAGC GCGCGCCAGG CGGTTTCTTA
660 AGTCTGATGT GAAAGCCAC GGTCAACCG TGGAGGGTCA TTGGAAACTG GGAACCTGA
720 GTGCAGAAAG GAAAGCGGA ATTCCACGTG TAGCGGTGAA ATGCGTAGAG ATGTGGAGGA
780 ACACCAAGTG CGAAGGCGGC TTTnTGGTCT GTAACnTGAC CTGAGGCGCG AAAGCGTGCG
840 GAGCAAAACAG GATTAGATAC CCTGGTAGTC CACGCCGTAA ACGATGAGTG CTAAGTGTTA
900 GAGGGTTTCC GCCCTTTAGT GCTGCAGCTA ACGCATTAAG CACTCCGCCCT GGGGAGTACG
960 GTCGCAAGAC TGAAACTCAA AGGAATTGAC GGGGCGCCGC ACAAGCGGTG GAGCATGTGG
1020 TTTAATTGGA AGCAACGCGA ARAACCTTAC CAGGTCTTGA CATCCTCTGA CAACTCTAGA
1080 GATAGAGCGT TCCCCTTCGG GGGACAGAGT GACAGGTGGT GCATGGTTGT CGTCAGCTCG
1140 TGTCTGTAGA TgTTGGGtA AGTCCCAGCA AGAGCGCAAC CCGTGTATCTT AGTTGCCAGC
1200 ATTTAGTTGG GCACTCTAAG GTGACTGCCG GTGACAAACC GGAGGAAGGT GGGGATGACG
1260 TCAAAATCATC ATGCCCTTAA TGACCTGGGC TACACACGTG CTACAATGGA TGGTACAAAG
1320 GGCTGCAAGA CCGCGAGGTC AAGCCAATCC CATAAAACCA TTCTCAGTTC GGATTGTAGG
1380 CTGCAACTCG CCTACATGAA GCTGGAATCG CTAGTAATCG CCGATCAGCA TGCCGCGGTG
1440 AATACGTTCC CGGGCCCTTGT ACACACCGCC CGTCACACCA CGAGAGTTTG TAACACCCGA
1500 AGTCGGTGA GTAACCGTAA GGAGCTAGCC GCCTAAGGTG GGACAGATGA TTGGGGTGAA
1515 GTCGTAACAA GTTAA

SUBSTITUTE SHEET (RULE 26)

- 8C

13/26

TCGGGACGGT CAGCACACGA GGAGCTTGCT CCTTGGGTGA CGAGTGGCGG ACGGTTGAGT 60
AATGTCTGGG GATCTGCCCC ATAnAGGGG ATAACCACTG GAAACGGTGG CTAATACCGC 120
ATAACGTCGC AAGACCAAAG AGGGGACCT TCGGGCTCT TCACTATCGA TGAACCCAGA 180
TGGGATTAGC TAGTAnCGG GGTAAATGGCC CACCTAGGCG ACGATCCCTA nCTGGTCTGA 240
GAGGATGACC AGCCACACTG GAACTGAGAC ACGTCCAnA CTCCTACGGG AGGCAGCAGT 300
GGGAATATT GCACAATGG CGCAAGCCTG ATGCAGCCAT GCCGCGTGTA TGAAGAAAGC 360
CTTCGGGTTG TAAAGTACTT TCAGCGGGGA GGAAGGCGAT GCGGTTAATA ACCCTGTCTGA 420
TTGACGTTCC CCGCAnGAAG AAGCACCGG TAACTCCGTG CCAGCAGCCG CCGTAATACC 480
GGAGGGTGCA AGCGTTAATC CGGAATTACT GGGCGTAAAG CGCACGCAGG CCGTCTGTTA 540
AGTCAGATGT GAAATCCCCG GGCTTAACCT GGGAACTGCA TTTGAAACTG GCAGGCTTGA 600
GTCTTGTAGA GGGGGTAGA ATTCCAGGTG TAGCGGTGAA ATGCGTAGAG ATCTGGAGGA 660
ATACCGGTGG CGAAGCGGC CCTTGGACA AAGACTGACG CTCAGGTGCG AAAGCGTGGG 720
GAGCAACAG GATTAGATAC CCTGGTAGTC CACGCCGTAA ACGATGTCGA CTTGGAGGTT 780
GTTCCCTTGA GGAGTGGCTT CCGGAGCTAA CGCGTTAAGT CGACCCCGCTG GGGAGTACGG 840
CCGCAAGGTT AAAATTCAA TGAATTGACG GGGGCCCGCA CAAGCGGTGG AGCATGTGGT 900
TTAATTCGAT GCAACGCGAA GAACCTTACC TACTCTTGAC ATCCAGCGAA CTTGCCAGAG 960
ATGGAATTGGT GCCTTCGGGA ACGCTGAGAC AGGTGCTGCA TGGCTGTCTGT CAGCTCGTGT 1020
TGTGAAATGT TGGGTTAAGT CCCGCAACGA GCGCAACCTT TATCCTTTGT TGCCAGCGAT 1080
TCGGTCGGGA ACTCAAAGGA GACTGCCGGT GATAAACCGG AGGAAGGTGG GGATGACGTC 1140
AAGTCATCAT GGCCCTTACG AGTAGGGCTA CACACGTGCT ACAATGGCGC ATACAAAAGAG 1200
AAGCGACCTC GCGAGAGCAA GCGGACCTCA CAAAGTGCGT CGTAGTCCGG ATCGGAGTCT 1260
GCAACTCGAC TCCGTGAAGT CGGAATCGCT AGTAATCGTG GATCAGAATG CCACGGTGAA 1320
TACGTTCCCG GGCCTTGTA ACACCGCCCG TCACACCATG GGAGTGGGT GCAAAAAGAG 1380
TAGGTAGCTT AACCTTCGGG AGGGCGCTTA CCACTTTGTG ATTCATGACT GGGGTGAAGT 1440
CGTAACAAAGT A 1451

14/26

60 AGAGTTTGAT CCTGGCTCAG GATGAACGCT GCGGCGGTGC CTAATACATG CAAGTCGAGC
120 GAATGGATTG AGAGCTTGCT CTCAAGAAAGT TAGCGGCGGA CCGGTGAGTA ACACGTGGGT
180 AACCTGCCCA TAAGACTGGG ATAACCTCGG GAAACCGGG CTAATACCGG ATAACATTTT
240 GAACTGCATG GTTCGAAATT GAAAGCGGC TTCGGCTGTC ACTTATGGAT GGACCCGCGT
300 CGCATTAGCT AGTTGGTGAG GTAAACGGCTC ACCAAGGCAA CGATGCGTAG CCGACCTGAG
360 AGGCTGATCG GCCACACTGG GACTGAGACA CCGCCAGAC TCCTACGGA GGCAGCAGTA
420 GGGAACTCTC CGCAATGGAC GAAAGTCTGA CGGAGCAACG CCGCGTGAGT GATGAAGGCT
480 TTCGGGTCGT AAAACTCTGT TGTAGGGA TGTAGGTA GAACAAAGTGC TAGTTGAATA AGCTGGCACC
540 TTGACCGTAC CTAACCAGAA AGCCACGGCT AACTACGTGC CAGCAGCCGC GGTAATACGT
600 AGGTGGCAAG CGTTATCCGG AATTATTGGG CGTAAAGCGC GCGCAGGTGG TTTCTTAGGT
660 CTGATGTGAA AGCCACCGC TCAACCGTGG AGGTCAATTG GAAACTGGGA GACTTGAGTG
720 CAGAAAGAGG AAGTGGAAAT CCATGTGTAG CGGTGAAATG CGTAGAGATA TGGAGGAACA
780 CCAGTGGCGA AGGCGACTTT CTGGTCTGTA ACTGACACTG AGGCGGAAA GCGTGGGAG
840 CAAACAGGAT TAGATACCCCT GGTAAGTCCAC GCGTAAACG ATGAGTGCTA AGTGTTAGAG
900 GGTTTCCGCC CTTTAGTGCT GAAGTTAACG CATTAAAGCAC TCCGCCCTGG GAGTACGGCC
960 GCAAGGCTGA AACTCAAAGG AATTGACGGG GGCCCGCACA AGCGGTGGAG CATGTGGTTT
1020 AATTCGAAGC AACGCGAAGA ACCTTACCAG GTCTTGACAT CCTCTGAAA CCCTAGAGAT
1080 AGGCTTCTC CTTCCGGAGC AGAGTGACAG GTGGTGCA TGTTGTCGTCA GCTCGTGTG
1140 TGAGATGTTG GGTTAAGTCC CGCAACGAGC GCAACCTTG ATCTTAGTTG CCATCATTA
1200 GTTGGGCACT CTAAGGTGAC TGCCGGTGAC AAACCGGAGG AAGGTGGGA TGACGTCAA
1260 TCATCATGYC CCTTATGACC TGGGCTACAC ACGTGCTACA ATGGACGTA CAAAGAGCTG
1320 CAAGACCGCG AGGTGGAGCT AATCTCATAA AACCGTTCTC AGTTCrGATT GTAGGCTGCA
1380 ACTCGCCTAC ATGAAGCTGG AATCGCTAGT AATCGCGGAT CAGCATGCCG CCGTGAATAC
1440 GTTCCCGGGC CTTGTACACA CCGCCCGTCA CACCACGAGA GTTTGTAAACA CCCGAAGTCG
1500 GTGGGGTAAC CTTTTTGGAG CCAGCCGCCT AAGGTGGGAC AGATGATTGG GGTGAAGTCG
1513 TAACAAGGTA GCC

SUBSTITUTE SHEET (RULE 26)

FEF - BE

15/26

AGAGTTTGAT CCTGGCTCAG GACGAACGCT GGCGGCGTGC CTAATACATG CAAGTCGAGC 60
GAACAGATGG GAGCTTGCTC CCTGATGTTA GCGCGGGACG GGTGAGTAAC ACGTGGGTAA 120
CCTGCCCTGTA AGACTGGGAT AACTCCGGGA AATCGGGGCT AATACCGGAT GGTGTTTGA 180
ACCGCATGGT TCAGACATAA AAGGTGGCTT CGGCTACCAC TTACAGATGG ACCCGCGGCG 240
CATTAGCTAG TTGGTGAGGT AACGGCTCAC CAAGGCGACG ATGCGTAGCC GACCTGAGAG 300
GGTGATCGGC CACACTGGGA CTGAGACACG GCCCAGACTC CTACGGGAGG CAGCAGTAGG 360
GAATCTTCCG CAATGGACGA AAGTCTGACG GAGCAACGCC GCGTGAGTGA TGAAGGTTTT 420
CGGATCGTAA AGCTCTGTTG TTAGGGAAGA ACAAGTGCCG TTCAAATAGG GCGGCACCTT 480
GACGGTACCT AACCAGAAAG CCACGGCTAA CTACGTGCCA GCAGCCGCGG TAATACGTAG 540
GTGGCAAGCG TTGTCCGGAA TTATTGGCGG TAAAGGGCTC GCAGGCGGTT TCTTAAGTCT 600
GATGTGAAAG CCCCCGGTTC AACGGGGGAG GGTCAATTGA AACTGGGGA CTTGAGTGCA 660
GAAAGAGGAGA GTGGAATTCC ACGTGTAGCG GTGAAATGCG TAGAGATGTG GAGGAACACC 720
AGTGGCGAAG GCGACTCTCT GGTCTGTAAC TGACGCTGAG GAGCGAAAGC GTGGGGAGCG 780
AACAGGATTA GATACCCTGG TAGTCCACGC CGTAAACGAT GAGTGCTAAG TGTAGGGGG 840
TTTCCGCCCC TTAGTGCTGC AGCTAACGCA TTAAGCACTC CGCCTGGGGA GTACGGTCGC 900
AAGACTGAAA CTCAAAGGAA TTGACGGGGG CCCGCACAAG CGGTGGAGCA TGTGGTTAA 960
TTCGAAGCAA CGCGAAGAAC CTTACCAGGT CTTGACATCC TCTGACAAATC CTAGAGATAG 1020
GACGTCCCTT TCGGGGGCAG AGTGACAGGT GGTGCAATGGT TGTCGTCAGC TCGTGTCTGT 1080
AGATGTTGGG TTAAGTCCC GCAACGAGCGC AACCTTGAT CTTAGTTGCC AGCATTTCAGT 1140
TGGGCACTCT AAGGTGACTG CCGGTGACAA ACCGGAGGAA GGTGGGGATG ACGTCAAATC 1200
ATCATGCCCC TTATGACCTG GGCTACACAC GTGCTACAAT GGCAGAAACA AAGGCGAGCG 1260
AAACCGCGAG GTTAAGCCAA TCCCACAAAT CTGTTCTCAG TTCGGATCGC AGTCTGCAAC 1320
TCGACTGCGT GAAGCTGGAA TCGCTAGTAA TCGCGGATCA GCATGCCGCG GTGAATACGT 1380
TCCCGGGCCT TGTACACACC GCCCGTCACA CCACGAGAGT TTGTAACACC CGAAGTCGGT 1440
GAGGTAACTT TTATGGAGCC AGCCGCCGAA GGTGGGACAG ATGATTGGGG TGAAGTCGTA 1500
ACAAGGTAAC CG 1512

SUBSTITUTE SHEET (RULE 26)

 BF

16/26

GCCTAACAGT GCGAGTCGGA CCGTAGCACA GAGGAGCTTG CTCTTCGGGT GACGAGTGCG 60
GGACGGGTGA GTAATGTCTG GGGATCTGCC CGATGGAGGG GGATAACCCAC TGGAAACGGT 120
GGCTAATACC GCATAATGTC GCAAGACCAA AGTGGGGGAC CTTCGGGCCT CACACCATCG 180
GATGAACCCA GATGGGATTA GCTAGTAGGT GGGGTAACGG CTCACCTAGG CGACGATCCC 240
TAGCTGGTCT GAGAGGATGA CCAGCCACAC TGGAACCTGAG ACACGGTCCA GACTCCTACG 300
GGAGGCAGCA GTGGGGAATA TTGCACAATG GCGCAAGCC TGATGCAGCC ATGCCGCGTG 360
TATGAAGAAG GCCTTCGGGT TGTAAAGTAC TTTCAnCGGG GAGGAAGGGG ACGAGGTTAA 420
TAACCCCGTT CATTGACGTT ACCCGCAGAA GAAGCACCGG CTAACCTCCGT GCCAGCAGCC 480
GCGGTAATAC GGAGGGTGCA AGCGTTAATC GGAATTACTG GGCGTAAAGC GCACGCAGGC 540
GGTCTGTTAA GTCAGATGTG AAATCCCGG GCTTAACCTG GGAACCTGCAT TTGAAACTGG 600
CAGGCTTGAG TCTTGTAGAG GGGGGTAGAA TTCCAGGTGT AGCGGTGAAA TGCGTAGAGA 660
TCTGGAGGAA TACCGGTGGC GAAGGCGGCC CCTGGACAA AGACTGACGT TCAGGTGCGA 720
AAGCGTGGG AGCAAACAGG ATTAGATACC CTGGTAGTCC ACGCCGTAAA CGATGTCGAC 780
TTGGAGGCTG TGAGCATGAT TCGTGGCTTC CCGAGCTAAC GCGTTAAGTC GACCGCCTGG 840
GGAGTACGGC CGCAAGGTTA AAATTCAAAT GAATTGACGG GGGCCCGCAC AAGCGGTGGA 900
GCATGTGGTT TAATTcGATG CAACGCGAAG AACCTTACCT GYTCTTGACA TCCACGGAAT 960
TyGGCAGAGA TGCCTTAGTG CCTTCGGGAA CCGTGAGACA GGTGCTGCAT GGCTGTCGTC 1020
AGCTCGTGTT GTGAAATGTT GGGTTAAGTC CCGCAACGAG CGCAACCTTT ATCCTTTGTT 1080
GCCAGCGATT CCGTCGGGAA CTCAAAGGAG ACTGCCGGTG ATAAACCCGA GGAAGGTGGG 1140
GATGACGTCA AGTCATCATG GCCCTTACGA GCAGGGCTAC ACACGTGCTA CAATGGCGCA 1200
TACAAAGAGA AGCGACCTCG CGAGAGCAAG CGGACCTCAC AAAGTGCCTC GTAGTCCGGA 1260
TCGGAGTCTG CAACCTCGACT CCGTGAAGTC GGAATCGCTA GTAATCGTGG ATCAGAATGC 1320
CACGGTGAAT ACGTTCCCGG GCCTTGATACA CACCGCCCGT CACACCATGG GAGTGGGTTG 1380
CAAAAGAAGT AGGTAGCTTA ACCTTCGGGA GGGCGCTTAC CACTTTGTGA TTCATGACTG 1440
GGTGAAGTC GTAACAAG 1458

SUBSTITUTE SHEET (RULE 26)

- 86

17/26

60 AGTGCAGATC GGACGGTAGC ACAGAGAGCT TGCTCTTGGG TGACGAGTGG CGGACGGGTG
120 AGTAATGTCT GGGGATCTGC CCGATAGAGG GGGATAACCA CTGGAACGG TGGCTAATAC
180 CGCATAACGT CGCAAGACCA AAGAGGGGA CCTTCGGGCC TCTCACTATC GGATGAACCC
240 AGATGGGATT AGCTAGTAGG CCGGGTAATG GCCACCTAG GCGACGATCC CTAGCTGGTC
300 TGAGAGGATG ACCAGCCACA CTGGAAGTGA GACACGGTCC AGACTCCTAC GGGAGGCAGC
360 AGTGGGGAAT ATTGCACAAT GGGCGCAAGC CTGATGCAGC CATGCCCGCT GTATGAAGAA
420 GGCCTTCGGG TTGTAAAGTA CTTTCAGCGG GGAGGAAGGC GATGCGGTTA ATAACCCTGT
480 CGATTGACGT TACCCGCAGA AGAAGCACCG GCTAACTCCG TGCCAGCAGC CGCGGTAATA
540 CCGAGGGTGC AAGCGTTAAT CGGAATTACT GGGCGTAAAG CGCACGCAGG CGGTCTGTTA
600 AGTCAGATGT GAAATCCCGG GGCTTAACCT GGGAACTGCA TTTGAAACTG GCAGGCTTGA
660 GTCTTGTAGA rGGGGGTAGA ATTCCAGGTG TAGCGGTGAA ATGCGTAGAG ATCTGGAGGA
720 ATACCGGTGG CGAAGGCGGC CCCCTGGACA AAGACTGACG CTCAGGTGCG AAAGCGTGGG
780 GAGCAAAACAG GATTAGATAC CCTGGTAGTC CACGCCGTAA ACGATGTCGA CTTGGAGGTT
840 GTTCCCTTGA GGAGTGGCTT CCGGAGCTAA CGCGTTAAGT CGACCGCCTG GGGAGTACGG
900 CCGCAAGGTT AAAATTCAA TGAATTGACG GGGGCCCGCA CAAGCGGTGG AGCATGTGTT
960 TTAATTTCGAT GCAACGCGAA GAACCTTACC TACTCTTGAC ATCCACGGAA TTYGGCAGAG
1020 ATGCTTTGGT GCCTTCGGGA ACCCTGAGAC AGGTGCTGCA TGGCTGTCGT CAGCTCGTGT
1080 TGTGAAAATGT TGGGTTAAGT CCCGCAACGA GCGCAACCTT TATCCTTTGT TGCCAGCGAT
1140 TCGGTCGGGA ACTCAAAGGA GACTGCCCGT GATAAACCAG AGGAAGGTGG GGATGACGTC
1200 AAGTCATCAT GGCCCTTACG AGTAGGGCTA CACACGTGCT ACAATGGCGC ATACAAAGAG
1260 AAGCGACCTC GCGAGAGCAA GCGGACCTCA CAAAGTGCCT CGTAGTCCGG ATCGGAGTCT
1320 GCAACTCGAC TCCGTGAAGT CGGAATCGCT AGTAATCGTG GATCAGAATG CCACGGTGAA
1380 TACGTTCCCG GGCCTTGTAC ACACCGCCCG TCACACCATG GGAGTGGGTT GCAAAGAAG
1440 TAGGTAGCTT AACCTTCGGG AGGGCGCTTA CCACCTTTGTG ATTCATGACT GGGGTGAAGT
1451 CGTAACAAAGT A

BH

18/26

AGAGTTTGAT CATGGCTCAG GATGAACGCT GCGGGCGTGC CTAATACATG CAAGTCGAGC 60
GAACTGATTA GAAGCTTGCT TCTATGACGT TAGCGGCGGA CCGGTGAGTA ACACGTGGGC 120
AACCTGCCCTG TAAGACTGGG ATAACTTCGG GAAACCGAAG CTAATACCGG ATAGGATCTT 180
CTCCTTCATG GGAGATGATT GAAAGATGGT TTCGGCTATC ACTTACAGAT GGGCCCGCGG 240
TGCATTAGCT AGTTGGTGAG GTAACGGCCC ACCAAGGCAA CGATGCATAG CCGACCTGAG 300
AGGTGATCG GCCACACTGG GACTGAGACA CCGCCCAGAC TCCTACGGA GGCAGCAGTA 360
GGGAATCTTC CGCAATGGAC GAAAGTCTGA CCGAGCAACG CCGCGTGAGT GATGAAGGCT 420
TTCGGGTCGT AAAACTCTGT TGTTAGGGAA GAACAAGTAC GAGAGTAACT GCTCGTACCT 480
TGACGGTACC TAACCAGAAA GCCACGGCTA ACTACGTGCC AGCAGCCCGG GTAATACGTA 540
GGTGGCAAGC GTTATCCGGA ATTATGGGC GTAAAGCGCG CCGCAGGCGG TTCTTTAAGT 600
CTGATGTGAA AGCCACCGC TCAACCGTG GATGGTCAAT GGAAACTGGG GAACTTGAGT 660
GCAGAAGAGA AAAGCGGAAT TCCACGTGTA GCGTGAAAT CCGTAGAGAT GTGGAGGAAC 720
ACCAAGTGGC AAGGCGGCTT TTTGGTCTGT AACTGACGCT GAGGCGCGAA AGCGTGGGA 780
GCAACACAGGA TTAGATACCC TGGTAGTCCA CGCCGTAAAC GATGAGTGCT AAGTGTTAGA 840
GGGTTTCCGC CCTTTAGTGC TGCAGCTAAC GCATTAAGCA CTCGCCCTGG GGAGTACGGT 900
CGCAAGACTG AAACCTCAAAG GAATTGACGG GGGCCCGCAC AAGCGGTGGA GCATGTGTT 960
TAATTGGAAG CAACGCGAAG AACCTTACCA GGTCTTGACA TCCTCTGACA ACTCTAGAGA 1020
TAGAGCTTTC CCCTTCGGG GACAGAGTGA CAGTGGTGTC ATGGTTGTCG TCAGTCCGTG 1080
TCGTGAGATG TTGGGTAAAG TCCCGCAACG AGCGCAACCC TTGATCTTAG TTGCCAGCAT 1140
TTAGTTGGGC ACTCTAAGGT GACTGCCGGT GACAAACCGG AGGAAGGTGG GGATGACGTC 1200
AAATCATCAT GCCCCTTATG ACCTGGGCTA CACACGTGCT ACAATGGATG GTACAAAGGG 1260
CTGCAAGACC GCGAGGTCAA GCCAATCCCA TAAAACCAAT CTCAGTTCGG ATTGTAGGCT 1320
GCAACTCGCC TACATGAAGC TGGAAATCGCT AGTAATCGCG GATCAGCATG CCGCGGTGAA 1380
TACGTTCCCG GGCCTTGATG ACACCGCCCG TCACACCCACG AGAGTTTGTA ACACCCGAAG 1440
TCGGTGGAGT AACCGTAAG AGCTAGCCCG CTAAGGTGGG ACAGATGATT GGGGTGAAGT 1500
CGTAACAAGG TAG 1513

SUBSTITUTE SHEET (RULE 26)

FILE - BI

19/26

60 CGCTGGGCGG CCTGCTTAAC ACnTGCAAGT CGAACGATGA TGCCCAGCTT GCTGGGTGGA
120 TTAGTGGCGA ACGGTGAGT AACACGTGAG TAACCTGCCC CTGACTCTGG GATAAGCGTT
180 GGAACGACG TCTAATACTG GATATGATCA CTGGCCGCAT GGTCTGGTGG TGGAAAGATT
240 TTTTGGTTGG GGATGGACTC GCGGCCATC AGCTTGTTGG TGAGGTAATG GCTCACCAAG
300 GCGACGACGG GTAGCCGGCC TGAGAGGGTG ACCGGCCACA CTGGGACTGA GACACGGCCC
360 AGACTCCTAC GSGAGGCAAC AGTGGGAAT ATTGCACAAT GGGCGAAAGC CTGATGCAGC
420 AACGCCGCGT GAGGGATGAC GGCCTTCGGG TTGTAAACCT CTTTTAGTAG GGAAGAAGCG
480 AAAGTGACGG TACCTGCAGA AAAAGCACCG GCTAACTACG TGCCAGCAGC CGCGGTAATA
540 CGTAGGGTGC AAGCGTTGTC CGGAATTATT GGGCGTAAAG AGCTCGTAGG CGGTTTGTCTG
600 CGTCTGCTGT GAAATCCCGA GGCTCAACCT CGGGCTTGCA GTGGGTACGG GCAGACTAGA
660 GTGCGGTAGG GGAGATTGGA ATTCTTGGTG TAGCGGTGGA ATGCGCAGAT ACCAGGAGGA
720 ACACCGATGG CGAAGGCAGA TCTCTGGGCC GTAACTGACG CTGAGGAGCG AAAGCATGGG
780 GAGCGAACAG GATTAGATAC CCTGGTAGTC CATGCCGTAA ACGTTGGCG CTAGATGTAG
840 GGACCTTTCC ACGGTTTCTG TGTCTAGTCT AACGCATTAA GCGCCCCGCC TGGGGAGTAC
900 GGGCGCAAGG CTAAAACTCA AAGGAATTGA CGGGGGCCCG CACAAGCGGC GGAGCATGCG
960 GATTAAATTCG ATGCAACGCG AAGAACCTTA CCAAGGmTG ACATACACCG GAAACGGCCA
1020 GAGATGGTCG CCCCCTTGTG GTCGGGTGTAC AGTGGTGCA TGGTTGTCGT CAGCTCGTGT
1080 CGTGAGATGT TGGGTTAAGT CCCGCAACGA GCGCAACCCT CGTCTATGT TGCCAGCGGG
1140 TTATGCCGGG GACTCATAGG AGACTGCCCG GGTCAACTCG GAGGAAGGTG GGGATGACGT
1200 CAAATCATCA TGCCCCTTAT GTCTTGGGCT TCACGCATGC TACAATGGCC GTACACAAGG
1260 GCTGCCGATAC CGTAAGGTGG AGCGAATCCC AAAAAGCCGG TCTCAGTTCTG GATTGAGGTC
1320 TGCAACTCGA CCTCATGAAG TCGGAGTCGC TAGTAATCGC AGATCAGCAA CGTGCCGGTG
1380 AATACGTTCC CGGGCCTTGT ACACACCGCC CGTCAAGTCA TGAAAGTCTGG TAACACCCGA
1440 AGCCGGTGGC CTAACCCCTTG TGGAAGGAGC CGTCGAAGGT GGGATCGGTG ATTAGGACTA
1452 AGTCGTAACA AG

SUBSTITUTE SHEET (RULE 26)



BJ

20/26


60 AGAGTTTGAT CATGGCTCAG AACGAACGCT GGCGGCATGC CTAACACATG CAAGTCGAAC
 120 GAGATCTTCG GATCTAGTGG CGCACGGGTG CGTAACGCgT GGAATCTGC cCTTtGGTTc
 180 GGAATAaCAG TTGGAAACGA CTGCTAATgA CCGGATGATG ACGTAAGTCC AAAGATTTAT
 240 CGCCAGAGGA TkAGCCCGCG TAGGATTAGC tAgTTGGTGT GGTaaGAGCG CACCAAGGCG
 300 ACgAtCCTTA GCTGTCTIGA GArGATGAtC AGCCACACTG GGAaGAGAc ACGGcCCAGa
 360 CTCCTACGGG AGGCAGCAGT GGGGAATwTT GGACAATGGG CGAAAGCCTG ATCCAGCAAT
 420 GCCGCGTGAG TGATGAAGGC CTTAGGGTTG TAAAGCTCTT TTACCCGGGA TGATAATGAC
 480 AGTACCGGGA GAATAAGCTC CGGCTAACTC CGTGCCAGCA GCCGCGGTAA TACGGAGGGA
 540 GCTAGCGTTG TTCGGAATTA CTGGCGGTAA AGCGCACGTA rCGGgCTTTG TAAgTTAGAG
 600 GTGAAAGCCT GGAGCTCAAC TCCAGAAATTG CCTTTAAGAC TGCATCGCTT GAATCCAGGA
 660 GAGGTGAGTG GAATTCCGAG TGTAAGAGTG AAATTCGTAG ATATTcGGAA GAACACCAGT
 720 GGCGAAAGCG GCTCACTGGA CTGGTATTGA CGCTGAGGTG CGAAAGCGTG GGGAGCAAAc
 780 AGGATTAGAT ACCCTGGTAG TCCACGCCGT AACCGATGAT AACTAGCTGT CCGGGGACTT
 840 GGTCCTTTGG TGCGGCAGCT AACGCATTAA GTTATCCGCC TGGGAGTAC GGCCGCAAGG
 900 TTAAAACTCA AATGAATTGA CGGGGGCCTG CACAAGCGGT GGAGCATGTG GTTTAAATTcG
 960 AAGCAACGCG CAGAAcCTTA CCAGCGTTTG ACATGTCCGG ACGATTtCTG GAGACAGATC
 1020 TCTTCCCTTC GGGGACTGGA ACACAGGTGC TGCATGGCTG TCGTCAGCTC GTGTcGTGAG
 1080 ATGTTGGGTT AAGTCCCGCA ACAGCGGCAa CCCTCGCCTT TAGTTACCAT CATTTAGTTG
 1140 GGGACTCTAA AGGAACCGCC GGTGATAAGC CGGAGGAAGG TGGGATGAC GTCAAGTCCT
 1200 CATGGCCCTT ACGCGCTGGG CTACACACGT GCTACAATGG CCGTGACAGT GGCAGCAAA
 1260 CTCGCGAGAG TGCGCTAATC TCCAAAAGCC GTCTCAGTTC GGATTGTtCT CTGCAACTCG
 1320 AGAGCATGAA GGCGGAATCG CTAGTAATCG CCGATCAGCA TGCCGCGGTG AATACGTTCC
 1380 CAGGCCTTGT ACACACCGCC CGTCACACCA TGGGAGTTGG GTTCACCCGA AGCGGTtGCG
 1440 CTAActCAGC AATGAGAGGC AGCGGACCAC GGTGGGCTTA GCGACTGGGG TGAAGTCGTA
 1450 ACAAGGTAAc

BK

21/26

FIG. 9AFIG. 9B



22/26

FIG. 10A



m/z	Assignment
447	(T-BzOH) ⁺
386	(T-H ₂ O-BzOH-AcOH) ⁺
326	(T-BzOH-2AcOH-H ₂ O) ⁺
308	(T-BzOH-2AcOH-2H ₂ O) ⁺

FIG. 10B



23/26

FIG. 11AFIG. 11B


24/26



25/26



26/26

FIG. 14C

SEQUENCE LISTING

<110> BCM Développement Inc.
 PAGÉ, Michel
 LANDRY, Nathalie
 BOISSINOT, Maurice
 HÉLIE, Marie-Claude
 HARVEY, Mario
 GAGNÉ, Martin

<120> BACTERIAL MASS PRODUCTION OF TAXANES AND
 PACLITAXEL

<130> 12637-2PCT FC/ld

<150> US 08/995,960

<151> 1997-12-22

<160> 13

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1556

<212> DNA

<213> Sphingomonas taxi

<400> 1

atgattacgc	caagctatgt	aggtgacact	atagaataact	caagctatgc	atccaacgcg	60
ttgggagctc	tcccatatgg	tcgacctgca	ggcggccgca	ctagtgatta	gagtttgatc	120
ctggctcaga	acgaacgctg	gcggcatgcc	taacacatgc	aagtcgaacg	agatcttcgg	180
atctagtggc	gcacgggtgc	gtaacgcgtg	ggaatctgcc	ctttggttcg	gaataacagt	240
tggaaacgac	tgctaatacc	ggatgatgac	gtaagtccaa	agatttatcg	ccagaggatg	300
agcccgcgta	ggattagcta	gttggtgtgg	taagagcgca	ccaaggcgac	gacoccttagc	360
tggtctgaga	ggatgatcag	ccacactggg	actgagacac	ggcccagact	cctacgggag	420
gcagcagtg	ggaatattgg	acaatggg	aaagcctgat	ccagcaatgc	cgcgtgagtt	480
gatgaaagcc	ttaggttgtt	aaagctcttt	taccgggaa	tgataatgac	agtaccggga	540
gaataagctc	cggctaactc	cgtgccagca	gccgcggtaa	tacggaagga	gctagcggtg	600
ttecggaatta	ctgggcgtaa	agcgcacgta	ggcggccttg	taagttagag	gtgaaagcct	660
ggagctcaac	tccagaattg	cctttaagac	tgcatcgctt	gaatccagga	gaggtgagtg	720
gaattccgag	tgtagagggtg	aaattcgtag	atattcgga	gaacaccagt	ggcgaaggcg	780
gctcactgga	ctggtattga	cgctgagggtg	cgaaagcgtg	gggagcaaac	aggattagat	840
accctggtag	tccacgccgt	aaacgatgat	aactagctgt	ccggggactt	ggtctttggg	900
tggcgcagct	aacgcattaa	gttatccgcc	tggggagtag	ggccgcaagg	ttaaaactca	960
aatgaattga	cgggggcctg	cacaagcggg	ggagcatgtg	gtttaattcg	aagcaacgcg	1020
cagaacctta	ccagcggttg	acatgtccgg	acgatttctg	gagacagatc	tcttcccttc	1080
ggggactgga	acgcaggtgc	tgcatggctg	tcgtcagctc	gtgtcgtgag	atgttgggtt	1140
aagtcgccga	acgagcgcaa	ccctcgccct	tagttacat	catttagttg	gggactctaa	1200
aggaaccgcc	ggtgataagc	cggaggaagg	tggggatgac	gtcaagtcct	catggccctt	1260
acgcgctggg	ctacacacgt	gctacaatgg	cggtgacagt	gggcagcaaa	ctcgcgagag	1320
tgcgctaatac	tccaaaagcc	gtctcagttc	ggattgttct	ctgcaactgc	agagcatgaa	1380
ggcggaatcg	ctagtaatcg	cggatcagca	tgccgcggtg	aatacgttcc	caggccttgt	1440
acacaccgcc	cgtcacacca	tgggagttgg	gttcaccgga	aggcgttgcg	ctaactcgta	1500
agagaggcag	gcgaccacgg	tgggcttagc	gactgggggtg	aagtcgtaac	aaggtta	1556

<210> 2
<211> 1512
<212> DNA
<213> *Bacillus cereus* ssp. *taxi*

<400> 2
agagtttgat catggctcag gatgaacgct ggcggcgctgc ctaatacatg caagtcgagc 60
gaatggatta agagcttgct cttatgaagt tagcggcgga cgggtgagta acacgtgggt 120
aacctaccca taagactggg ataactccgg gaaaccgggg ctaataccgg ataatatatt 180
gaactgcata gttcgaaatt gaaaggcggc ttccggctgc acttatggat ggacccgcgt 240
cgcattagct agttggtgag gtaacggctc accaaggcga cgatgcgtag ccgacctgag 300
agggtgatcg gccacactgg gactgagaca cggcccagac tcctacggga ggcagcagta 360
gggaatcttc cgcaatggac gaaagtctga cggagcaacg ccgctgagat gatgaaggct 420
ttcgggtcgt aaaactctgt tggttagggaa gaacaagtgc tagttgaata agctggcacc 480
ttgacgggtac ctaaccagaa agccacggct aactacgtgc cagcagcccg cggtaatacg 540
taggtggcaa gcgttatccg gaattattgg gcgtaaagcg cgcgcagggtg gtttcttaag 600
tctgatgtga aagcccacgg ctcaaccgtg gagggtcatt ggaaactggg agacttgagt 660
gcagaagagg aaagtggaaat tccatgtgta gcggtgaaat gcgtagagat atggaggaac 720
accagtggcg aaggcgactt tctggtctgt aactgacact gaggcgcgaa agcgtgggga 780
gcaaacagga ttagataccc tggtagtcca cgccgtaaac gatgagtgt aagtgttaga 840
gggtttccgc cctttagtgc tgaagttaac gcattaagca ctccgcctgg ggagtacggc 900
cgcaaggctg aaactcaaag gaattgacgg gggcccgcac aagcgggtgga gcatgtggtt 960
taattcgaag caacgcgaag aaccttacca ggtcttgaca tcctctgaaa actctagaga 1020
tagagcttct ccttcggggag cagagtgaac ggtggtgcat ggttgcctgc agctcgtgtc 1080
gtgagatgtt ggggttaagtc ccgcaacgag cgcaaccctt gatcttagtt gccatcatta 1140
agttgggcac tctaagggtga ctgccggtga caaacgggag gaaggtgggg atgacgtcaa 1200
atcatcatgc cccttatgac ctgggctaca cacgtgccac aatggacggt acaaagagct 1260
gcaagaccgc gaggtggagc taatctcata aaaccgttct cagttcggat tgtaggctgc 1320
aactcgcta catgaagctg gaatcgctag taatcgcgga tcagcatgcc gcggtgaata 1380
cgttcccggg ccttgtacac accgcccgtc acaccacgag agtttgaac acccgaagtc 1440
gggtggggtaa cctttatgga gccagccgac taaggtggga cagatgattg ggggtgaagtc 1500
gtaacaaggt aa 1512

<210> 3
<211> 1515
<212> DNA
<213> *Bacillus megaterium* ssp. *taxi*

<400> 3
agagtttgat cctggctcag gatgaacgct ggcggcgctgc ctaatacatg caagtcgagc 60
gaactgatta gaagcttgct tctatgacgt tagcggcgga cgggtgagta acacgtgggc 120
aacctgcctg taagactggg ataactccgg gaaaccgaag ctaataccgg ataggatctt 180
ctccttcatt ggggatgatt gaaagatggt ttccggctatc acttacagat gggcccgcgg 240
tgcatttagct agttggtgag gtaacggctc accaaggcaa cgatgcatag ccgacctgag 300
agggtgatcg gccacactgg gactgagaca cggcccaaac tcctacggga ggcagcagta 360
gggaatcttc cgcaatggac gaaagtctga cggagcaacg ccgctgagat gatgaaggct 420
ttcgggtcct aaaactctgt tggttnggaa gaacaaatac cagagtaact gcttgttctt 480
tgacggtacc taaccagaaa gccacggcta actactttcc agcagcccg gtaatacnta 540
tggtggcaag cgttatccgg aattattggg gcgttaaagc gcgcgccagg cggtttctta 600
agtctgatgt gaaagcccac ggctcaaccg tggagggtca ttggaaactg gggaacttga 660
gtgcagaaga gaaaagcggg attccacgtg tagcgggtgaa atgcgtagag atgtggagga 720
acaccagtgg cgaaggcggc tttttggtct gtaactgacg ctgaggcgcg aaagcgtggg 780
gagcaaacag gattagatac ccttggtagtc cacgccgtaa acgatgagt ctaagtgtta 840
gagggtttcc gccctttagt gctgcagcta acgcattaag cactccgcct ggggagtagc 900
gtcgaagac tgaactcaa aggaattgac gggggcccgc acaagcgggt gagcatgtgg 960
tttaattcga agcaacgcga araaccttac caggtcttga catcctctga caactctaga 1020

gatatagcgt	tcccccttcg	gggacagagt	gacaggtggt	gcatggttgt	cgtcagctcg	1080
tgctcgtgaga	tggtgggtta	agtccccgaa	cgagcgcaac	ccttgatctt	agttgccagc	1140
athtagttgg	gcactctaag	gtgactgccg	gtgacaaacc	ggaggaaggt	ggggatgacg	1200
tcaaatacatc	atgccccctta	tgacctgggc	tacacacgtg	ctacaatgga	tggtacaaaag	1260
ggctgcaaga	ccgcgaggtc	aagccaatcc	cataaaacca	ttctcagttc	ggattgtagg	1320
ctgcaactcg	cctacatgaa	gctggaatcg	ctagtaatcg	cggatcagca	tgccgcggtg	1380
aatacgttcc	cgggccttgt	acacaccgcc	cgtcacacca	cgagagtttg	taacaccgga	1440
agtcggtgga	gtaaccgtaa	ggagctagcc	gcctaagggt	ggacagatga	ttggggtgaa	1500
gtcgtatacaa	ggtaa					1515

<210> 4

<211> 1451

<212> DNA

<213> Pantoea sp. BCM 1

<400> 4

tcgggacggt	cagcacacga	ggagcttgct	ccttgggtga	cgagtggcgg	acgggtgagt	60
aatgtctggg	gatctgccc	atanaggggg	ataaccactg	gaaacgggtg	ctaataccgc	120
ataacgtcgc	aagaccaaa	agggggacct	tcgggacctt	cactatcgga	tgaaccaga	180
tggttagtagc	tagtangcgg	ggtaatggcc	cacctaggcg	acgatcccta	nctggctcga	240
gaggatgacc	agccacactg	gaactgagac	acggtccana	ctcctacggg	aggcagcagt	300
ggggaatatt	gcacaatggg	cgcaagcctg	atgcagccat	gccgcgtgta	tgaagaaggc	360
cttcgggttg	taaagtactt	tcagcgggga	ggaaggcgat	gcggttaata	accctgtcga	420
ttgacgttcc	ccgcangaag	aagcaccggc	taactccgtg	ccagcagccg	cggtaatacc	480
ggaggggtgca	agcgttaatc	cggaattact	gggcgtaaag	cgcacgcagg	cggtctgtta	540
agtcagatgt	gaaatcccc	ggcttaacct	gggaactgca	tttgaactg	gcaggcttga	600
gtcctttaga	ggggggtaga	attccagggt	tagcggtgaa	atgcgtagag	atctggagga	660
ataccggtgg	cgaaggcgcc	cccttggaca	aagactgacg	ctcaggtgcg	aaagcgtggg	720
gagcaaacag	gattagatac	cctggtagtc	cacgccgtaa	acgatgtcga	cttggaggtt	780
gttcccttga	ggagtggctt	ccggagctaa	cgcggttaag	cgaccgcctg	gggagtacgg	840
ccgcaaggtt	aaaattcaaa	tgaattgacg	ggggcccgcg	caagcgggtg	agcatgtggt	900
ttaattcgat	gcaacgcgaa	gaaccttacc	tactcttgac	atccagcgaa	cttgccagag	960
atggattggt	gccttcggga	acgctgagac	aggtgctgca	tggtgtgctg	cagctcgtgt	1020
tgtgaaatgt	tggtttaagt	cccgcacaga	gcgcacacct	tatcctttgt	tgccagcgat	1080
tcggtcggga	actcaaaagg	gactgccggt	gataaaaccg	aggaaggtgg	ggatgacgtc	1140
aagtcatcat	ggcccttacg	agtagggcta	cacacgtgct	acaaatggcg	atacaaagag	1200
aagcgacctc	gcgagagcaa	gcggacctca	caaagtgcgt	cgtagtccgg	atcggaagtct	1260
gcaactcgac	tccgtgaagt	cggaaatcgt	agtaatcgtg	gatcagaatg	ccacggtgaa	1320
tacgttcccc	ggccttgtag	acaccgcccg	tcacaccatg	ggagtgggtt	gcaaaagaag	1380
taggttagctt	aaccttcggg	agggcgctta	ccactttgtg	attcatgact	ggggtgaagt	1440
cgtaacaagt	a					1451

<210> 5

<211> 1513

<212> DNA

<213> Bacillus cereus ssp. BCM 4

<400> 5

agagtttgat	cctggctcag	gatgaacgct	ggcggcgctg	ctaatacatg	caagtcgagc	60
gaatggattg	agagcttgct	ctcaagaagt	tagcggcgga	cgggtgagta	acacgtgggt	120
aacctgccca	taagactggg	ataactccgg	gaaaccgggg	ctaataccgg	ataacatttt	180
gaactgcacg	gttcgaaatt	gaaaggcgcc	ttcggtctgc	acttatggat	ggaccgcgct	240
cgcattagct	agttggtgag	gtaacggctc	accaaggcaa	cgatgcgtag	ccgacctgag	300
agggtgatcg	gccacactgg	gactgagaca	cggcccagac	tcctacggga	ggcagcagta	360
gggaatcttc	cgcaatggac	gaaagtctga	cggagcaacg	ccgcgtgagt	gatgaaggct	420

ttcgggtcgt	aaaactctgt	tggttagggaa	gaacaagtgc	tagttgaata	agctggcacc	480
ttgacgggtac	ctaaccagaa	agccacggct	aactacgtgc	cagcagccgc	ggtaatacgt	540
aggtggcaag	cgttatccgg	aattattggg	cgtaaagcgc	gcgcaggtgg	tttcttaggt	600
ctgatgtgaa	agcccacggc	tcaaccgtgg	agggtcattg	gaaactggga	gacttgagtg	660
cagaagagga	aagtgggaatt	ccatgtgtag	cgggtgaaatg	cgtagagata	tggaggaaca	720
ccagtggcga	aggcgacttt	ctgggtctgta	actgacactg	aggcgcgaaa	gcgtggggag	780
caaacaggat	tagataccct	ggtagtccac	gccgtaaacg	atgagtgcta	agtgttagag	840
ggtttccgcc	ctttagtgtc	gaagttaacg	cattaagcac	tccgcctggg	gagtacggcc	900
gcaaggctga	aactcaaagg	aattgacggg	ggcccgcaca	agcgggtggag	catgtggttt	960
aattcgaagc	aacgcgaaga	accttaccag	gtcttgacat	cctctgaaaa	ccctagagat	1020
agggcttctc	cttcggggagc	agagtgcacg	gtggtgcattg	gttgctgcga	gctcgtgtcg	1080
tgagatgttg	ggttaagtcc	cgcaacgagc	gcaacccttg	atcttagttg	ccatcattaa	1140
gttgggcact	ctaagggtgac	tgccgggtgac	aaaccggagg	aaggtgggga	tgacgtcaaa	1200
tcatcatgyc	ccttatgacc	tgggtacac	acgtgctaca	atggacggta	caaagagctg	1260
caagaccgcg	aggtggagct	aatctcataa	aaccgttctc	agttcrgatt	gtaggctgca	1320
actcgcctac	atgaagctgg	aatcgctagt	aatcgcggat	cagcatgccg	cggtgaatac	1380
gttcccgggc	cttgtacaca	ccgcccgtca	caccacgaga	gtttgtaaca	cccgaagtcg	1440
gtggggtaac	ctttttggag	ccagccgcct	aagtggggac	agatgattgg	gggtgaagtcg	1500
taacaaggta	gcc					1513

<210> 6

<211> 1512

<212> DNA

<213> *Bacillus subtilis* ssp. *taxi*

<400> 6

agagtttgat	cctggctcag	gacgaacgct	ggcggcgtgc	ctaatacatg	caagtcgagc	60
gaacagatgg	gagcttgctc	cctgatgtta	gcgccggacg	ggtagtaac	acgtgggtaa	120
cctgcctgta	agactgggat	aactccggga	aatccgggct	aataccggat	ggttgtttga	180
accgcatggg	tcagacataa	aaggtggcct	cggctaccac	ttacagatgg	accgcggcg	240
cattagctag	ttggtgaggt	aacggctcac	caaggcgacg	atgcgtagcc	gacctgagag	300
ggatgatcgg	cacactggga	ctgagacacg	gcccagactc	ctacgggagg	cagcagtagg	360
gaatcttccg	caatggacga	aagtctgacg	gagcaacgcc	gcgtgagtga	tgaaggtttt	420
cggatcgtaa	agctctgttg	ttaggggaaga	acaagtgccg	ttcaaataag	gcggcacctt	480
gacggtaacct	aaccagaaaag	ccacggctaa	ctacgtgccg	gcagccggcg	taatacgtag	540
gtggcaagcg	ttgtccggaa	ttattgggcg	ttaaagggtc	gcaggcgggt	tcttaagtct	600
gatgtgaaag	cccccggttc	aacgggggag	ggtcattgga	aactggggaa	cttgagtgcg	660
gaagaggaga	gtggaattcc	acgtgtagcg	gtgaaatgcg	tagagatgtg	gaggaacacc	720
agtggcggaag	gcgactctct	ggtctgtaac	tgacgctgag	gagcgaaagc	gtggggagcg	780
aacaggatta	gataccctgg	tagtccacgc	cgtaaacgat	gagtgtctag	tgtagggggg	840
tttccgcccc	ttagtgtctg	agctaacgca	ttaagcactc	cgccctggga	gtacggctcg	900
aagactgaaa	ctcaaaggaa	ttgacggggg	ccgcacaaag	cgggtggagca	tgtggtttta	960
ttcgaagcaa	cgcaagaac	cttaccaggt	cttgacatcc	tctgacaatc	ctagagatag	1020
gacgtcccct	tcgggggagc	agtgcagagt	gggtgcattg	tgctgctcgc	tcgtgtcgtg	1080
agatgttggg	ttaagtcccc	caacgagcgc	aacccttgat	cttagttgcc	agcattcagt	1140
tgggcactct	aaggtgactg	ccggtgacaa	accggaggaa	ggtaggggatg	acgtcaaatac	1200
atcatgcccc	ttatgacctg	ggctacacac	gtgctacaat	gggcagaaca	aagggcgagc	1260
aaaccgcgag	gttaagccaa	tcccacaaat	ctgttctcag	ttcggatcgc	agtctgcaac	1320
tcgactgctg	gaagctggaa	tcgctagtaa	tcgcgatca	gcagccgcg	gtgaatacgt	1380
tcccgggcct	tgtacacacc	gcccgtcaca	ccacgagagt	ttgtaacacc	cgaagtcggt	1440
gaggtaacct	ttatggagcc	agccgccgaa	ggtagggacg	atgattgggg	tgaagtcgta	1500
acaaggtaac	cg					1512

<210> 7
 <211> 1458
 <212> DNA
 <213> Pantoea sp. BCM 2

<400> 7

gcctaacagt	gagagtcgga	cggtagcaca	gaggagcttg	ctcttcgggt	gacgagtggc	60
ggacgggtga	gtaatgtctg	gggatctgcc	cgatggaggg	ggataaccac	tggaaacggc	120
ggctaatacc	gcataatgtc	gcaagaccaa	agtgggggac	cttcgggcct	cacaccatcg	180
gatgaaccca	gatgggatta	gctagtaggt	ggggtaacgg	ctcacctagg	cgacgatccc	240
tagctgggtc	gagaggatga	ccagccacac	tggaaactgag	acacgggtcca	gactcctacg	300
ggaggcagca	gtggggaata	ttgcacaatg	ggcgcaagcc	tgatgcagcc	atgccgcgtg	360
tatgaagaag	gccttcgggt	tgtaaagtac	tttcancggg	gaggaagggg	acgagggttaa	420
taaccccggt	cattgacgtt	acccgcagaa	gaagcaccgg	ctaactccgt	gccagcagcc	480
gcggttaatac	ggagggtgca	agcgttaatc	ggaattactg	ggcgtaaagc	gcacgcaggc	540
ggtctgttaa	gtcagatgtg	aaatccccgg	gcttaacctg	ggaactgcat	ttgaaactgg	600
caggcttgag	tctttagtag	gggggtagaa	ttccaggtgt	agcggtgaaa	tgcgtagaga	660
tctggaggaa	taccggtggc	gaaggcggcc	ccctggacaa	agactgacgt	tcagggtgca	720
aagcgtgggg	agcaaacagg	attagatacc	ctggtagtc	acgccgtaaa	cgatgtcgac	780
ttggaggctg	tgagcatgat	tcgtggcttc	cggagctaac	gcgttaagtc	gaccgcctgg	840
ggagtacggc	cgcaagggtta	aaattcaaat	gaattgacgg	gggcccgcac	aagcggtgga	900
gcatgtggtt	taattcgatg	caacgcgaag	aaccttacct	gytcttgaca	tccacggaat	960
tyggcagaga	tgcttagtg	ccttcgggaa	ccgtgagaca	ggtgctgcat	ggctgtcgtc	1020
agctcgtggt	gtgaaatggt	gggttaagtc	ccgcaacgag	cgcaaccct	atcctttgtt	1080
gccagcgatt	cggtcgggaa	ctcaaaggag	actgccggtg	ataaaccgga	ggaagggtggg	1140
gatgacgtca	agtcacatg	gcccttacga	gcagggtac	acacgtgcta	caatggcgca	1200
tacaaagaga	agcgacctcg	cgagagcaag	cggacctcac	aaagtgcgtc	gtagtccgga	1260
tcggagtctg	caactcgact	ccgtgaagtc	ggaatcgcta	gtaatcgctg	atcagaatgc	1320
caagggtgaat	acgttcccgg	gccttgtaga	caccgcccg	cacaccatgg	gagtggtgtg	1380
caaaagaagt	aggtagctta	accttcggga	gggcgcttac	cactttgtga	ttcatgactg	1440
gggtgaagtc	gtaacaag					1458

<210> 8
 <211> 1451
 <212> DNA
 <213> Pantoea sp. BCM 3

<400> 8

agtgcgagtc	ggacggtagc	acagagagct	tgctcttggg	tgacgagtgg	cggacgggtg	60
agtaaatgtc	ggggatctgc	ccgatagagg	gggataacca	ctggaaacgg	tggctaatac	120
cgcataacgt	cgcaagacca	aagaggggga	ccttcggggc	tctcactatc	ggatgaaccc	180
agatgggatt	agctagtagg	cggggtaatg	gcccacctag	gcgacgatcc	ctagctggtc	240
tgagaggatg	accagccaca	ctggaactga	gacacgggtc	agactcctac	gggaggcagc	300
agtggggaat	attgcacaat	gggcgcaagc	ctgatgcagc	catgcccgct	gtatgaagaa	360
ggccttcggg	ttgtaaagta	ctttcagcgg	ggaggaaggc	gatgcggtta	ataaccctgt	420
cgattgacgt	taccgcgaga	agaagcaccg	gctaactccg	tgccagcagc	cgcggtaata	480
cggagggtgc	aagcgttaat	cggaattact	gggcgtaaag	cgcacgcagg	cggctctgtta	540
agtcagatgt	gaaatccccg	ggcttaacct	gggaactgca	tttgaaactg	gcaggcttga	600
gtcttgtaga	rgggggtaga	attccagggtg	tagcgggtgaa	atgcgtagag	atctggagga	660
ataccgggtg	cgaaggcggc	cccctggaca	aagactgacg	ctcagggtcg	aaagcgtggg	720
gagcaaacag	gattagatac	cctggtagtc	cacgcctgaa	acgatgtcga	cttggagggt	780
gttccttgga	ggagtggctt	ccggagctaa	cgctgtaagt	cgaccgcctg	gggagtcagg	840
ccgcaagggt	aaaattcaaa	tgaattgacg	ggggcccgcg	caagcgggtg	agcatgtggt	900
ttaattcgat	gcaacgcgaa	gaaccttacc	tactcttgac	atccacggaa	tttyggcagag	960
atgctttggt	gccttcggga	accttgagac	aggtgctgca	tggctgtcgt	cagctcgtgt	1020
tgtgaaatgt	tgggttaagt	cccgcacaag	gcgcaacct	tatcctttgt	tgccagcgat	1080

tcggtcggga	actcaaagga	gactgccggt	gataaaccgg	aggaaggtgg	ggatgacgtc	1140
aagtcacat	ggcccttacg	agtagggcta	cacacgtgct	acaatggcgc	atacaaagag	1200
aagcgacctc	gcgagagcaa	gcggacctca	caaagtgcgt	cgtagtccgg	atcggagtct	1260
gcaactcgac	tccgtgaagt	cggaatcgct	agtaatcgty	gatcagaatg	ccacggtgaa	1320
tacgttcccc	ggccttgta	acaccgcccc	tcacaccatg	ggagtgggtt	gcaaaagaag	1380
taggtagctt	aaccttcggg	agggcgctta	ccactttgtg	attcatgact	ggggtgaagt	1440
cgtaacaagt	a					1451

<210> 9

<211> 1513

<212> DNA

<213> Bacillus megaterium ssp. BCM 9

<400> 9

agagtttgat	catggctcag	gatgaacgct	ggcggcgtgc	ctaatacatg	caagtcgagc	60
gaactgatta	gaagcttgct	tctatgacgt	tagcggcggg	cgggtgagta	acacgtgggc	120
aaactgcctg	taagactggg	ataacttcgg	gaaaccgaag	ctaataccgg	ataggatctt	180
ctccttcacg	ggagatgatt	gaaagatggg	ttcggctatc	acttacagat	gggcccgcgg	240
tgcattagct	agttgggtgag	gtaacggccc	accaaggcaa	cgatgcatag	ccgacctgag	300
aggggtgatcg	gccacactgg	gactgagaca	cggcccagac	tcctacggga	ggcagcagta	360
gggaatcttc	cgcaatggac	gaaagtctga	cggagcaacg	ccgcgtgagt	gatgaaggct	420
ttcgggtcgt	aaaactctgt	tgtaggggaa	gaacaagtac	gagagtaact	gctcgtacct	480
tgacgggtacc	taaccagaaa	gccacggcta	actacgtgcc	agcagccggc	gtaatacgtg	540
gggtggcaagc	gttatccgga	attattgggc	gtaaagcgcg	ccgcaggcgg	ttctttaagt	600
ctgatgtgaa	agcccacggc	tcaaccgtgg	garggtcatt	ggaaactggg	gaacttgagt	660
gcagaagaga	aaagcggaat	tccacgtgta	gcggtgaaat	gcgtagagat	gtggagggaac	720
accagtggcg	aaggcggctt	tttggtctgt	aactgacgct	gaggcgcgaa	agcgtgggga	780
gcaaacagga	ttagataccc	tgtagtcca	cgccgtaaac	gatgagtgtc	aagtgttaga	840
gggttttcgc	cctttagtgc	tgtagctaac	gcattaaagca	ctccgcctgg	ggagtacggt	900
cgcaagactg	aaactcaaa	gaattgacgg	gggcccgcac	aagcggtgga	gcatgtggtt	960
taattcgaag	caacgcgaag	aaccttacca	ggtcttgaca	tcctctgaca	actctagaga	1020
tagagctttc	cccttcgggg	gacagagtga	cagggtggtg	atggttgctg	tcagctcgtg	1080
tcgtgagatg	ttgggttaag	tcccgcaacg	agcgcaaccc	ttgatcttag	ttgccagcat	1140
ttagttgggc	actctaagg	gactgccggt	gacaaaccgg	aggaaggtgg	ggatgacgtc	1200
aaatcatcat	gccccttatg	acctgggcta	cacacgtgct	acaatggagt	gtacaaaggg	1260
ctgcaagacc	gagaggtcaa	gccaatccca	taaaaccatt	ctcagttcgg	attgtaggct	1320
gcaactcgcc	tacatgaagc	tggaatcgct	agtaatcgcg	gatcagcatg	ccgcggtgaa	1380
tacgttcccc	ggccttgta	acaccgcccc	tcacaccacg	agagtttgta	acaccggaag	1440
tcggtggagt	aaccgtaagg	agctagccgc	ctaaggtggg	acagatgatt	ggggtgaagt	1500
cgtaacaagg	tag					1513

<210> 10

<211> 1452

<212> DNA

<213> Curtobacterium sp. BCM 5

<400> 10

cgctggggcg	cctgcttaac	acntgcaagt	cgaacgatga	tgcccagctt	gctgggtgga	60
ttagtgggcg	acgggtgagt	aacacgtgag	taacctgccc	ctgactctgg	gataagcgtt	120
ggaaacgacg	tctaatactg	gatatgatca	ctggccgcat	ggtctggtgg	tggaaagatt	180
ttttggttgg	ggatggactc	gcggcctatc	agcttgttgg	tgaggtaatg	gctcaccaag	240
gcgacgacgg	gtagccggcc	tgagaggggtg	accggccaca	ctgggactga	gacacggccc	300
agactcctac	gggaggcaac	agtggggaat	attgcacaat	gggcgaaagc	ctgatgcagc	360
aacgccgcgt	gagggatgac	ggccttcggg	ttgtaaacct	cttttagtag	ggaagaagcg	420
aaagtgacgg	tacctgcaga	aaaagcaccg	gctaactacg	tgccagcagc	cgcggtaata	480

cgtaggggtgc	aagcgttgct	cggaattatt	gggcgtaaag	agctcgtagg	cggtttgtcg	540
cgtctgctgt	gaaatcccga	ggctcaacct	cggtcttgca	gtgggtacgg	gcagactaga	600
gtgcggtagg	ggagattgga	attcctgggtg	tagcgggtgga	atgcgcagat	accaggaggga	660
acaccgatgg	cgaaggcaga	tctctgggcc	gtaactgacg	ctgaggagcg	aaagcatggg	720
gagcgaacag	gattagatac	cctggtagtc	catgccgtaa	acgttgggcg	ctagatgtag	780
ggacctttcc	acgttttctg	tgctgtagct	aacgcattaa	gcgccccgcc	tggggagtac	840
ggccgcaagg	ctaaaactca	aaggaattga	cgggggcccc	cacaagcggc	ggagcatgcg	900
gattaattcg	atgcaacgcg	aagaacctta	ccaaggmttg	acatacaccg	gaaacggcca	960
gagatggtcg	cccccttggt	gtcgggtgac	aggtgggtgca	tggttgtcgt	cagctcgtgt	1020
cgtgagatgt	tgggttaagt	cccgcaccca	gcgcaaccct	cgttctatgt	tgccaaggcg	1080
ttatgccggg	gactcatagg	agactgccgg	ggtcaactcg	gaggaaggtg	gggatgacgt	1140
caaatcatca	tgcccccttat	gtcttgggct	tcacgcgatgc	tacaatggcc	gggtacaaagg	1200
gctgcgatac	cgtaagggtg	agcgaatccc	aaaaagccgg	tctcagttcg	gattgaggtc	1260
tgcaactcga	cctcatgaag	tcggagtcgc	tagtaatcgc	agatcagcaa	cgctgcgggtg	1320
aatacgttcc	cgggccttgt	acacaccgcc	cgtaagtcga	tgaaagtcgg	taacacccga	1380
agccggtggc	ctaacccttg	tgggaaggagc	cgtcgaaggt	gggatcgggtg	attaggacta	1440
agtcgtaaca	ag					1452

<210> 11

<211> 1450

<212> DNA

<213> *Sphingomonas* sp. BCM 7

<400> 11

agagtttgat	catggctcag	aacgaacgct	ggcggcatgc	ctaacacatg	caagtcgaac	60
gagatcttcg	gatctagtgg	cgacacgggtg	cgtaacgcgt	gggaatctgc	cctttggttc	120
ggaataacag	ttggaaacga	ctgctaataga	ccggatgatg	acgtaagtc	aaagatttat	180
cgccagagga	tkagcccgcg	taggattagc	tagttgggtg	ggtaagagcg	caccaaggcg	240
acgatcctta	gctggtctga	gargatgatc	agccacactg	ggactgagac	acggcccaga	300
ctcctacggg	aggcagcagt	ggggaatwtt	ggacaatggg	cgaaagcctg	atccagcaat	360
gccgcgtgag	tgatgaaggc	cttaggggtg	taaagctcct	ttaccgggga	tgataatgac	420
agtaccggga	gaataagctc	cggtctaactc	cgtgccagca	gccgcggtaa	tacggaggga	480
gctagcgttg	ttcgggaatta	ctgggcgtaa	agcgcacgta	rgcggccttg	taagttagag	540
gtgaaaagcct	ggagctcaac	tccagaattg	cctttaagac	tgcatcgctt	gaatccagga	600
gaggtgagtg	gaattccgag	tgtagagggtg	aaattcgtag	atattcgga	gaacaccagt	660
ggcgaaggcg	gctcactgga	ctgggtattga	cgctgagggtg	cgaaagcgtg	gggagcaaac	720
aggattagat	accctggtag	tccacgccgt	aaacgatgat	aactagctgt	ccggggactt	780
ggtctttggg	tggcgcagct	aacgcattaa	gttatccgcc	tggggagtac	ggccgcaagg	840
ttaaaactca	aatgaattga	cgggggcctg	cacaagcggg	ggagcatgtg	gtttaattcg	900
aagcaacgcg	cagaacctta	ccagcgtttg	acatgtccgg	acgatttctg	gagacagatc	960
tcttcccttc	ggggactgga	acacagggtgc	tgcatggctg	tcgtcagctc	gtgtcgtgag	1020
atgttgggtt	aagtcccgcg	acgagcgcaa	ccctcgctt	tagttaccat	catttagttg	1080
gggactctaa	aggaaccgcc	ggtgataagc	cggaggaagg	tggggatgac	gtcaagtcct	1140
catggccctt	acgcgctggg	ctacacacgt	gctacaatgg	cggtgacagt	gggcagcaaa	1200
ctcgcgagag	tgcgctaata	tccaaaagcc	gtctcagttc	ggattgttct	ctgcaactcg	1260
agagcatgaa	ggcggaatcg	ctagtaatcg	cggatcagca	tgccgcgggtg	aatacgttcc	1320
caggccttgt	acacaccgcc	cgctcacacca	tgggagttgg	gttcacccga	aggcgttgcg	1380
ctaactcagc	aatgagaggc	aggcgaccac	ggtgggctta	gcgactgggg	tgaagtcgta	1440
acaaggtaac						1450

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 12
agagtttgat cmtggctcag

20

<210> 13
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 13
tacggytacc ttgttacgac tt

22

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/01150

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12P17/02 C12N3/00 C12N1/00 C12N15/01 C12N1/20 C12P7/62 C12P7/26 //(C12P17/02,C12R1:07),(C12P17/02, C12R1:125) According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12P C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used)														
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>WO 95 04154 A (NIPPON STEEL CORPORATION) 9 February 1995 see page 5; claims 1-10 ---</td> <td>1-57</td> </tr> <tr> <td>X</td> <td>WO 96 34972 A (BCM DEVELOPMENT INC.) 7 November 1996 cited in the application see the whole document ---</td> <td>1-57</td> </tr> <tr> <td>X</td> <td>EP 0 668 360 A (BRISTOL-MYERS SQUIBB COMPANY) 23 August 1995 see page 6 - page 7; claims 1-21 --- -/--</td> <td>1-57</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO 95 04154 A (NIPPON STEEL CORPORATION) 9 February 1995 see page 5; claims 1-10 ---	1-57	X	WO 96 34972 A (BCM DEVELOPMENT INC.) 7 November 1996 cited in the application see the whole document ---	1-57	X	EP 0 668 360 A (BRISTOL-MYERS SQUIBB COMPANY) 23 August 1995 see page 6 - page 7; claims 1-21 --- -/--	1-57
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	WO 95 04154 A (NIPPON STEEL CORPORATION) 9 February 1995 see page 5; claims 1-10 ---	1-57												
X	WO 96 34972 A (BCM DEVELOPMENT INC.) 7 November 1996 cited in the application see the whole document ---	1-57												
X	EP 0 668 360 A (BRISTOL-MYERS SQUIBB COMPANY) 23 August 1995 see page 6 - page 7; claims 1-21 --- -/--	1-57												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.														
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "d" document member of the same patent family														
Date of the actual completion of the international search 27 May 1999		Date of mailing of the international search report 10/06/1999												
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Douschan, K												

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/CA 98/01150

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, L	CHEMICAL ABSTRACTS, vol. 130, 1999 Columbus, Ohio, US; abstract no. 174870, JAZIRI, M. ET AL: "A new concept for the isolation of bioactive taxoids" XP002103986	1-40
Y	see abstract & CURR. TOP. PHYTOCHEM. (1997), 1, 67-76 CODEN: CTPHFK,	41-57
X	--- CHEMICAL ABSTRACTS, vol. 128, Columbus, Ohio, US; abstract no. 202215, HANSON, RONALD L. ET AL: "Enzymic hydrolysis of 7-xylosyltaxanes by xylosidase from Moraxella sp." XP002103987	6
Y	see abstract & BIOTECHNOL. APPL. BIOCHEM. (1997), 26(3), 153-158 CODEN: BABIEC; ISSN: 0885-4513,	1-5, 7-57
X	--- WO 96 32490 A (NOVOPHARM LIMITED) 17 October 1996	6
Y	see page 1 - page 6; claims 1-9	1-5, 7-57
X	--- WO 97 16200 A (MERCK & CO., INC.) 9 May 1997	6
Y	cited in the application see the whole document	18-30
Y	--- WO 93 21338 A (THE RESEARCH AND DEVELOPMENT INSTITUTE, INC.) 28 October 1993	1-57
Y	cited in the application see claims 1-33 --- STROBEL, G. ET AL.: "Taxol from Pestalotiopsis microspora, an endophytic fungus of Taxus wallachiana" MICROBIOLOGY, vol. 142, 1996, pages 435-440, XP002103985 cited in the application see the whole document -----	1-57

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01150

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9504154	A	09-02-1995	JP 7177879 A	18-07-1995
WO 9634972	A	07-11-1996	US 5561055 A	01-10-1996
			AU 5494696 A	21-11-1996
			CA 2220081 A	07-11-1996
EP 0668360	A	23-08-1995	AT 178945 T	15-04-1999
			AU 693827 B	09-07-1998
			AU 1015695 A	27-07-1995
			CA 2138674 A	14-07-1995
			CN 1111229 A	08-11-1995
			DE 69508987 D	20-05-1999
			FI 950137 A	14-07-1995
			HU 70987 A	28-11-1995
			JP 7203981 A	08-08-1995
			US 5700669 A	23-12-1997
WO 9632490	A	17-10-1996	AU 5265696 A	30-10-1996
WO 9716200	A	09-05-1997	AU 7529396 A	22-05-1997
WO 9321338	A	28-10-1993	US 5322779 A	21-06-1994
			AU 675428 B	06-02-1997
			AU 4102093 A	18-11-1993
			CA 2140935 A	17-10-1993
			EP 0672168 A	20-09-1995
			JP 7505778 T	29-06-1995
			US 5861302 A	19-01-1994